Document:

exv10w23

 

EXHIBIT 10.23

ANIMAS CORPORATION

SUMMARY OF DIRECTOR AND EXECUTIVE COMPENSATION

     Director Compensation. As compensation for their service as directors, each of our
non-employee directors receives an option to purchase 10,000 shares of our common stock upon
election to our board of directors at one of our annual stockholder meetings. If a non-employee
director is initially elected to our board of directors at any time other than at an annual
stockholder meeting, the number of shares of his or her initial option award will be reduced
pro-rata to reflect his or her service during the period between the date that he or she is first
elected to our board of directors and the date of our next annual stockholder meeting. In
addition, non-employee directors receive an additional option to purchase 10,000 shares of our
common stock on the earlier of the date of our annual stockholder meeting or July 1st of each year
for each successive year that such non-employee director serves on our board of directors.

     As compensation for service on our audit committee, at each annual stockholder meeting, each
member of the audit committee receives an option to purchase 1,250 shares of our common stock, and
the chairman of our audit committee receives an additional option to purchase 625 shares of our
common stock. Also at each annual stockholder meeting, each member of our compensation and our
governance and nominating committees receives an option to purchase 750 shares of our common stock
and the chairman of each of these committees each receives an additional option to purchase 375
shares of our common stock. If a non-employee director joins a committee or becomes chairman of a
committee at any time other than within the forty-five day period following the date of one of our
annual stockholder meetings, his or her option award for committee service will be pro-rated for
the period between the date that he or she is elected and the date of our next annual stockholder
meeting.

     All stock options to non-employee directors will have an exercise price equal to the fair
market value of our common stock on the date of grant. Non-employee director options will vest
quarterly over the one-year period following the date of grant and will automatically become fully
vested and exercisable on the date of a change of control.

     Directors who are also our employees do not receive compensation for service as a member of
our board of directors or any of our committees of our board of directors, however all directors
are reimbursed for out-of-pocket expenses incurred in connection with attendance at meetings of our
board of directors and our committees of our board of directors.

     Executive Compensation. The following table sets forth current base salaries of our CEO and
each of the executive officers who are expected to be named in the Summary Compensation Table in
our Annual Report on Form 10-K for the year ending December 31, 2005 (the “Named Executive
Officers”). 

 

 

	 	 	 	 	 
	Name	 	Base Salary	 
	Katherine D. Crothall
	 	$	330,000	 
	Richard Baron
	 	$	235,000	 
	Audrey Finkelstein
	 	$	235,000	 
	James McGee
	 	$	215,000	 
	John Holly
	 	$	185,000	 

     Our compensation committee has approved a bonus plan, which is not set forth in a written
agreement, for certain management-level employees, including the Named Executive Officers. Under
this plan, if Animas achieves certain EBITDA targets approved by the compensation committee, we
will establish a fixed bonus pool to be paid out to eligible participants. Each eligible
participant’s bonus will be funded from this fixed pool and will be based upon a percentage of that
participant’s base salary.

     The Named Executive Officers are also eligible to participate in the 2004 Equity Incentive
Plan, the 2004 Employee Stock Purchase Plan, as well as our broad-based benefit programs generally
available to salaried employees, including health, disability and life insurance programs, and
qualified 401(k) plan. Each Named Executive Officer is also a party to the Animas Form of Change
of Control Agreement.exv10w24

 

EXHIBIT 10.24

Portions of this exhibit were omitted and filed separately with the Secretary of the
Commission pursuant to an application for confidential treatment filed with the
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934. Such
portions are marked by a series of asterisks.

LICENSE, JOINT DEVELOPMENT,

AND MANUFACTURING ASSISTANCE AGREEMENT

Recitals.

Parties. This Agreement is entered into as of October 29, 2004 between
Debiotech S.A., a Swiss company having a place of business at 28 Avenue de Sevelin, CH-1004
Lausanne, Switzerland, and Animas Corporation, a Delaware corporation having a place of
business at 200 Lawrence Drive, West Chester, PA 19380, USA.

Development Funding and License. Debiotech is prepared to undertake the
development of an externally worn micro-pump for the delivery of insulin based upon
Debiotech’s Micro Electro-Mechanical Systems technology and related know-how. Animas
desires to have exclusive rights to make, use sell and/or import such a pump and to obtain
exclusive license rights to all of Debiotech Intellectual Property useful for such purpose
for all uses relating to the administration of insulin.

Confidentiality Agreement. Debiotech and Animas entered into a confidential
disclosure agreement dated July 6, 2004. Upon execution of this Agreement, the
Confidentiality Agreement shall be terminated and replaced with the terms of this Agreement.

Term Sheet. Debiotech and Animas signed on August 31, 2004 a Term Sheet
containing most of the material terms upon which they intended to agree and providing a
basis for this Agreement. Upon execution of this Agreement, the Term Sheet shall be
terminated and replaced with the terms of this Agreement.

Parallel Agreement. Simultaneously with the execution of this Agreement,
Debiotech and Animas shall enter into a parallel License, Joint Development and
Manufacturing Assistance Agreement in connection with a micro-needle product of Debiotech.

Due-Diligence Prior to Agreement Signed. Prior to signature of this Agreement,
Animas has conducted a due diligence review of Debiotech’s relevant technology and related
manufacturing, Debiotech having provided all information requested by Animas, as well as a
further due diligence review relating to such relevant technology, including intellectual
property.

Consideration. In consideration of the mutual promises and obligations
contained herein, the parties agree as set forth in this Agreement.

 

 

1. Definitions

The following capitalized terms are used in this Agreement with the meanings indicated or
referred to below.

1.1 Affiliate: any corporation, partnership, limited liability company or other
enterprise or organization that directly or indirectly through one or more
intermediaries controls, is controlled by, or is under common control with a party,
where “control” means beneficial ownership of at least fifty percent (50%) of the then
outstanding voting shares or equity interests in the party in question or the power to
direct or otherwise cause the direction of the management and policy of the party in
question (for the avoidance of doubt, Existing Shareholders listed under Exhibit D
shall not be considered Affiliates given their current ownership of Animas).

1.2 Agreement: this LICENSE, JOINT DEVELOPMENT, AND MANUFACTURING ASSITANCE
AGREEMENT and all attached exhibits, together with any future amendments entered into
in accordance with Section 16.13 of this Agreement.

1.3 Agreement Date: the date on which this Agreement is entered into by the
Parties.

1.4 Animas: Animas Corporation, a Delaware corporation having a place of business
at 200 Lawrence Drive, West Chester, PA 19380, USA.

1.5 Animas Group: Animas and its Affiliates.

1.6 Annual Royalties Statement: a statement prepared by Animas at the end of each
Year in accordance with Section 4.6 of this Agreement, setting forth the Net Revenue
relating to Pump Products subject to a royalty in that Year. The Annual Royalty
Statement shall set forth (i) the number of Pump Products placed or sold to end-users,
by product and by country, and the Net Revenue, by product and by country, associated
with such Pump Products; (ii) the number of Pump Products placed or sold to
distributors, by product and by country, and the Net Revenue, by product and by
country, associated with such Pump Products; (iii) the number of Pump Products placed
or sold by Sub-licensees, by product and by country, and Net Payments received by
Animas from Sub-licensees associated with such Pump Products; and (iv) the royalties
payable by Animas with respect to such Net Revenue for that Year and the Sublicense
Fees payable by Animas with respect to such Net Payments from Sub-licensees for that
Year, if any, and the royalties and Sublicense Fees previously shown due in the
Quarterly Royalties Statements for that Year.

1.7 Change of Control: a change of control of Animas Group shall be deemed to have
occurred at such time as any third party, other than an Existing Shareholder listed

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

under Exhibit D, acquires more than 50% of the voting stock of Animas or Animas
merges with a third party except where Animas is the surviving entity. A Change of
Control will be deemed to have occurred if this Agreement is assigned directly or
indirectly to a third party, excluding an Animas Affiliate, including without
limitation the sale of substantially all of the assets of Animas in accordance with
Section 16.6 of this Agreement.

1.8 Commercial Launch: the date at which the first Pump Product is sold to an
end-user in any country, directly or indirectly, by a Licensee.

1.9 Debiotech: Debiotech S.A., a Swiss company having a place of business at 28
Avenue de Sevelin, CH-1004 Lausanne, Switzerland (together with successors and assigns,
and those Affiliates who (i) own Debiotech Intellectual Property or (ii) have license
rights therein in the Field, or (iii) employ any personnel having been involved as an
employee of Debiotech (including successors and assigns) or an Affiliate in the
development of an externally worn micro-pump utilizing MEMS technology).

1.10 Debiotech Intellectual Property: all patents, copyrights, trade secrets,
know-how and other intellectual property related to or useful to an externally-worn
micro-pump utilizing MEMS technology owned by, developed by or licensed to Debiotech,
now or until such time as the license granted pursuant to this Agreement is terminated
in accordance with Section 15 of this Agreement or becomes a fully paid-up license in
accordance with Section 2.2 of this Agreement (including, without limitation, the
intellectual property described more specifically in Exhibit A). Debiotech
Intellectual Property includes, without limitation, all ideas, methods, concepts,
design features, diagrams, schematics, flowcharts, specifications, code (source and
object) and any other intellectual property necessary or useful for Animas to fully
exercise its rights and perform its obligations under this Agreement or otherwise
commercialize Pump Products in the Field. Notwithstanding the foregoing, Debiotech
Intellectual Property shall include intellectual property developed jointly by
Debiotech and a third party unless Debiotech is prohibited by contractual agreement
with such third party to license such intellectual property to another party.

1.11 Debiotech Pump: an externally worn micro-pump system for the delivery of
insulin incorporating a MEMS Chip and based upon Debiotech Intellectual Property. In
its initial configuration, a Debiotech Pump will comprise both a MEMS Pump and a Pump
Controller according to the Specifications.

1.12 Debiotech Pump System: a system incorporating Debiotech Pump including Pump
Accessories.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

1.13 Development Program: the development program described more fully in Article
5 of this Agreement pursuant to which Debiotech is to use commercially reasonable
efforts to develop fully functional prototypes of the Debiotech Pump which meet the
Specifications.

1.14 Distributors: Third parties (outside Animas Group) that distribute Pump
Products sold to them by a Licensee.

1.15 FDA Approval: 510(k) clearance by the Food and Drug Administration (FDA) for
sale in the United States of the Debiotech Pump.

1.16 FDA Submission: filing for FDA Approval.

1.17 Field: all uses of an externally worn micro-pumps relating to the
administration of insulin which insulin may be administered through a single pump,
alone or in combination with other medications (such as glucagon and insulin).

1.18 Filling System: all the components necessary to fill and refill the Debiotech
Pump with insulin, such as insulin vial adaptor(s), syringes to apply pressure or
vacuum, external cartridge (if any), needles, caps, cleaning and sterilizing supplies
and the like.

1.19 Infusion Accessories: all components used together with the Debiotech Pump
System, such as Infusion Sets, prolongation sets, automatic placement tool for Infusion
Sets, carrying case, PC software and interface, printer, and the like.

1.20 Infusion Sets: all sterile infusion sets to be used in conjunction with the
Debiotech Pump.

1.21 Knowledge: “to the best knowledge of Debiotech” shall mean to the actual or
implied knowledge, as of the Agreement Date, of the officers, directors, owners and
management of Debiotech; provided that, “implied knowledge” shall mean only the
knowledge readily obtainable from all information available in the books, records and
files of Debiotech.

1.22 License: the exclusive license granted to Animas pursuant to Section 2.1 of
this Agreement (including further extensions to future rights, in particular in
accordance with Section 13.1 of this Agreement and Section 13.2 of this Agreement).

1.23 Licensed Patents: all patents, patent applications and patent rights included
in Debiotech Intellectual Property as well as patents, patent applications and patent
rights resulting from joint inventions under Section 13.1 of this Agreement. A

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

comprehensive list of such Licensed Patents, as of the Agreement Date, is described
in Exhibit A.

1.24 Licensees: Animas, Affiliates of Animas and Sub-licensees.

1.25 License Shares: 400’000 shares of restricted Animas Common Stock to be
delivered by Animas to Debiotech in accordance with Section 3.2 of this Agreement.

1.26 Major Countries: France, Germany, United Kingdom and United States.

1.27 Manufacturing Program: The manufacturing program as defined in Section 7.3 of
this Agreement.

1.28 MEMS: Micro Electromechanical Systems using fabrication techniques similar to
those utilized in the micro-electronics industry.

1.29 MEMS Chip: the silicon/Pyrex micro-chip pump utilizing Debiotech Intellectual
Property.

1.30 MEMS Pump: replaceable/disposable housing containing MEMS Chip, piezo
actuator, insulin reservoir (if any) and related internal components.

1.31 MEMS Pump Business: the business of Debiotech relating specifically to the
design, development and production of externally worn micro-pumps utilizing MEMS
technology and all licensing, consulting and investment activities and operations
relating thereto, whether in the Field or outside the Field.

1.32 Micro-Needle Agreement: a parallel agreement entered into between Debiotech
and Animas in connection with a micro-needle product of Debiotech, entitled
Micro-Needle License, Joint Development and Manufacturing Assistance Agreement and all
attached exhibits, together with any future amendments entered into in accordance with
such parallel agreement.

1.33 Net Revenue: gross revenue of Animas Group on a consolidated basis (excluding
all revenue from Sublicensees) from the sale of Pump Products to distributors and
end-users minus contractual allowances and discounts, as calculated in accordance with
US Generally Accepted Accounting Principles, as such principles are in effect at that
time, and as recognized in accordance with Animas’ standard accounting practices in
effect for the relevant period, consistently applied (“GAAP”).

1.34 Patient Installed Base: Installed base of patients under Debiotech Pump System
estimated as of July 1 of any Year considered.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

1.35 Pump Accessories: Filling Systems, Infusion Sets and all other Infusion
Accessories.

1.36 Pump Controller: long-term use (about ******) module, containing all the
hardware and firmware necessary to control and monitor the MEMS Pump and also providing
user interface means, as well as any other device related therewith (e.g. remote
programming system, including as the case may be a strip blood glucose monitoring
device, and the like).

1.37 Pump Products: products constituting Debiotech Pump System, i.e. MEMS Pump,
Pump Controller and Pump Accessories collectively or separately, including components
therein and assemblies into such products.

1.38 Quarterly Royalties Statement: a statement prepared by Animas for a calendar
quarter in accordance with Section 4.5 of this Agreement, setting forth the Net Revenue
of products subject to a royalty in that quarter (with relevant figures of units placed
to end-users and to distributors and Net Revenues, product by product and country by
country), the Net Payments received by Animas from Sub-licensees in that quarter and
the royalties and Sub-license Fees due by Animas with respect to such Net Revenues and
such Net Payments from Sub-licensees.

1.39 Royalties Term: the period during which at least one Licensed Patent is Valid
in at least one Major Country.

1.40
******-License: the non-exclusive license from ****** in favor of
Debiotech with regard to certain patents, including the right to sub-license.

1.41 Specifications: the specifications set forth in Exhibit B, as such
specifications may be amended, pursuant to this Agreement.

1.42 Steering Group: a six person committee composed of three senior employees of
each party, but not their CEO’s, which shall review in accordance with Section 5.5 of
this Agreement all the developmental, logistical and technical aspects of the
Development Program.

1.43 Sub-licensees: third party (outside Animas Group) sub-licensees appointed by
Animas in accordance with Section 2.3 of this Agreement and distributing Pump Products
which have not been sold to them by Animas Group or a Sub-licensee (so that such Pump
Products have not yet been taken into account for determining royalties due to
Debiotech). Sub-licensees do not include (i) parties that manufacture Pump Products,
or components therein, on behalf of Animas, but do not distribute such Pump Products or
components therein, or (ii) Distributors. However, the parties acknowledge that, the
same person might be a Distributor in connection with certain Pump Products (bought
from Animas Group or a Sub-licensee, e.g. Debiotech

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Pumps) and a Sub-licensee in connection with certain other Pump Products (not bought
from Animas Group or a Sub-licensee, e.g. Infusion Sets).

1.44 Valid: qualifier for a patent in a determined country, meaning that such
patent in such country is valid, not expired and has not been declared unenforceable by
a competent body of such country (such as a United States Federal District Court) for
any defect related to the patent (such as a failure from patentee to make relevant
disclosures) and affecting its validity lato sensu, but not making the patent
technically invalid. Whether the validity of the patent is challenged and infringers
can effectively be prevented is irrelevant to determine whether any patent is Valid.

1.45 Year: a calendar year, from January 1 to December 31.

2. License to Animas.

2.1 Exclusive License. Debiotech hereby grants to Animas an exclusive, even as to
Debiotech, worldwide license, with the right to sublicense in accordance with Section
2.3 of this Agreement, under all Debiotech Intellectual Property, excluding
intellectual property jointly developed by Debiotech and a third party, and a
non-exclusive sub-license under (i) the ******-License and (ii) Debiotech Intellectual
Property jointly developed by Debiotech and a third party, to make, have made, use,
sell, offer for sale, or import Debiotech Pump System in the Field. During the term of
this Agreement, Debiotech shall not enter into any agreement with any other party to
develop an externally-worn micro-pump utilizing MEMS technology for use in the Field.

2.2 Duration. The License shall be perpetual (subject to Article 15 of this
Agreement). After the Royalties Term, the License shall become a fully paid-up,
royalty free, irrevocable, non-exclusive worldwide license.

2.3 Sublicense. The License shall include the right for Animas to sublicense the
licensed rights; provided that Animas obtains Debiotech’s written consent which consent
shall not be unreasonably withheld or delayed. Animas’ sub-licensees shall conform to
the applicable material terms of this Agreement and Animas shall remain directly liable
to Debiotech with regard to any breach of the terms of this Agreement by Animas’
sub-licensees remaining uncured after a 90 day period following a default notice;
provided that, Animas shall no longer be considered in breach of this Section 2.3 in
the event Animas terminates the sublicense agreement within a reasonable period after
the breach.

2.4 Limitation to the Field. Licensees shall not make, use, sell, offer for sale,
or import Pump Products outside the Field.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

2.5 Further Documents. Debiotech hereby agrees to execute, or cause its employees,
partners, licensors, agents, or consultants to execute all documents and shall take all
actions necessary or desirable to effect, confirm and perfect the rights granted to
Animas pursuant to the License, including without limitation, assignment to Debiotech
of inventions past, present and future from its employees and consultants.

2.6 Promotion. Animas shall use reasonable commercial efforts to commercialize the
Debiotech Pump, independent of the economic attractiveness of other competing Animas
products.

2.7 Sales, Marketing and Distribution. All sales, marketing, and distribution
activities for Pump Products shall be the responsibility of Animas. Animas shall give
Debiotech periodic updates on the progress of Animas marketing activities.

3. License Fees.

3.1 Initial License Fee: Part in Cash. Animas shall pay to Debiotech a
non-refundable license fee of Twelve Million Dollars ($12,000,000), payable within 10
days following Agreement Date.

3.2 Initial License Fee: Part in Shares. Animas shall deliver to Debiotech the
License Shares, deliverable within 10 days following Agreement Date. In the event
Debiotech sells any of the License Shares while termination by Animas under Section
15.1(c) of this Agreement would still be permissible, Debiotech shall provide to Animas
a bank guarantee, letter of credit, escrow arrangement or such other form of security
acceptable to Animas to secure the termination payment payable to Animas pursuant to
Section 15.1(c) of this Agreement.

3.3 Restriction for sale of shares. The License Shares shall be issued pursuant to
the Subscription Agreement attached hereto as Exhibit E.

3.4 Additional License Fee. Animas shall pay Debiotech a one-time additional
license fee (“Additional License Fee”), subject to the provisions of this Section 3.4,
at such time as Debiotech provides Animas all deliverables reasonably necessary for
Animas to complete the FDA Submission (“FDA Deliverables”). A list of such FDA
Deliverables is included in Exhibit I and may be amended by Animas as reasonably
necessary, up to the date which is nine (9) months prior to the due date for delivery
of FDA Deliverables as set forth in the Development Program. To the extent, at any
time, Animas substantially modifies the FDA Deliverables (e.g. based on new
requirements by the FDA, changes in the market conditions, or the need to perform
clinical studies prior to FDA Submission), the dates below shall be extended to the
extent reasonably necessary for Debiotech to deliver additional FDA Deliverables.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

The Additional License Fee shall be Two Million Dollars ($2,000,000) if FDA
Deliverables have been received by Animas prior to January 1, 2007 if there has been
no Change of Control, or prior to July 1, 2007 if there has been a Change of
Control. The Additional License Fee shall be One Million Dollars ($1,000,000) if
FDA Deliverables have been received by Animas after January 1, 2007 but prior to
July 1, 2007 if there has been no Change of Control, or after July 1, 2007 but prior
to January 1, 2008 if there has been a Change of Control. If Animas paid a One
Million Dollars Additional License Fee, but a Two Million Dollars Additional License
Fee would be due following a Change of Control, the unpaid part of the Additional
License Fee shall be due within 30 days following Change of Control. This license
fee is payable only one-time even if multiple submissions are made to FDA. The
Additional License Fee, to the extent paid by Animas pursuant to this Section 3.4,
shall be payable within 30 days after Debiotech provides Animas with FDA
Deliverables. Except as set forth in the following two sentences, no Additional
License Fee shall be payable if FDA Deliverables are received by Animas after
January 1, 2008. The dates of January 1, 2007, July 1, 2007 and January 1, 2008
shall each be extended (i) for such number of days as the Steering Group agrees to
extend the Development Program in accordance with Section 5.5, and/or (ii) to the
extent delays of the development of the Pump Controllers and/or Infusion Accessories
impacts the delivery by Debiotech of the FDA Deliverables, for each day that the
development of the Pump Controllers and/or Infusion Accessories in accordance with
the Development Program is delayed by Animas. If Animas decides to perform clinical
trials prior to FDA Submission, the Additional License Fee shall be Two Million
Dollars ($2,000,000) and shall be paid within 30 days after Debiotech provides
Animas with FDA Deliverables, irrespective of the deadlines above.

3.5 Advance on Royalties. In the event of a Change of Control, Animas (or its
successor) shall pay Debiotech, a non-refundable advance on future royalties of Five
Million Dollars ($5,000,000), which payment shall be made within 180 days following a
Change of Control. No advance payment shall be due if, within 180 days following a
Change of Control, this Agreement is terminated in accordance with Section 15.1 or
15.2(c) of this Agreement.

Such advance payment shall be credited against 50% of actual royalty payments made
pursuant to Section 4.1 of this Agreement until such credit has been fully utilized.

3.6 Sublicense Fees. Except to the extent a Sub-licensee Royalty Rate is
applicable, Animas shall pay to Debiotech ****** of any Net Payments Animas receives
from Sub-licensees and Distributors (“Base Sub-licensee Rate”) . Net Payments equal the
gross cash (including royalties) received by Animas Group from Sub-licensees pursuant
to any sub-license agreement between Animas Group and such Sub-licensee relating to
Debiotech Intellectual Property and the gross cash received by Animas

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Group from Distributors pursuant to any agreement between Animas Group and such
Distributor relating to Debiotech Intellectual Property but excluding any cash
received by Animas Group from sales of Pump Products to such Distributors (provided
that, to the extent Debiotech can demonstrate that a substantial portion of the
sales price of Pump Products sold by Animas Group to Distributors includes what
should be characterized as a sublicense fee or royalties due to Animas Group,
Debiotech may require that such part of the sales price be included in the Net
Payments instead of in the Net Revenue), minus applicable import, export and excise
duties and sales tax (including VAT), and minus any taxes withheld from the gross
cash (excluding any taxes that were withheld after the gross cash payable to Animas
Group was increased to provide that after the withholding of the taxes Animas Group
was to receive the same amount of payment it would have received but for the
withholding) to the extent not recoverable by Animas Group within two years of the
receipt of the gross cash. In the event either (i) the total aggregate number of
Debiotech Pumps sold by all Sub-licensees and sold by Animas Group to Distributors
for resale outside the USA in a Year exceeds ****** of all Debiotech Pumps sold by
Animas Group (including those to Distributors) and its Sub-licensees in such Year,
or (ii) the total aggregate number of Infusion Sets sold by all Sub-licensees and
sold by Animas Group to Distributors for resale outside the USA in a Year exceeds
****** of all Infusion Sets sold by Animas Group (including those to Distributors)
and its Sub-licensees in such Year, Animas shall pay to Debiotech a Sub-licensee
License Fee equal to the greater of (i) a royalty equal to ****** of net revenues
of Pump Products sold by all Sub-licensees (“Sub-licensee Royalty Rate”), or (ii)
Base Sub-licensee Rate.

3.7 Currency. All payments under this Agreement shall be made in US Dollars, and
all references in this Agreement to “Dollars” shall mean “US Dollars”. Payments to be
made to Debiotech shall be made by SWIFT bank transfer to Debiotech’s bank account.

4. Royalties.

4.1 Base royalties. Animas agrees to pay Debiotech a royalty equal to a percentage
of Net Revenue of Pump Products sold or placed by Animas Group. The royalty rate shall
vary (based on Patient Installed Base) and shall be fixed each Year as set forth on
Exhibit H, except for certain adjustments as provided in Sections 4.3 and 4.4, in this
Agreement, when applicable.

4.2 Allocation of Net Revenues. In the event the Pump Products are sold in
combination with a product(s) that is not a Pump Product, such as insulin, a continuous
glucose monitoring device and related accessories (“Non-Pump Products”), the applicable
royalty on Pump Products shall be based on the Net Revenue of Pump Products as if

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

they were sold on a stand-alone basis (excluding additional net revenue for
Non-Pump Products).

In such case, Animas will give written notice to Debiotech of a proposed allocation
of the Net Revenue attributable to Pump Products sold with Non-Pump Products.
Following such notice, to the extent Debiotech does not agree with Animas’ proposed
allocation, the parties shall negotiate in good faith for a period of ninety (90)
days. If the parties are unable to agree on an allocation, either party may require
that the matter be determined by binding baseball arbitration pursuant to Section
16.2 of this Agreement.

4.3 Net Revenue Adjustment. In the event that less than ****** of Debiotech Pumps
placed to end-users or sold by Animas Group in any given Year are placed to end-users
or sold through its direct sales force, the parties shall negotiate in good faith an
appropriate correction factor of the Net Revenue for that Year, which correction factor
shall increase royalty payments payable to Debiotech to compensate, in part, for the
reduced average selling prices of Debiotech Pumps, and hence royalties to Debiotech, as
a result of the lower percentage of direct sales. The parties in such negotiations
shall consider a correction factor to provide for what the average selling price of
Pump Products would have been had Animas Group sold at least ****** of Debiotech Pumps
through its direct sales force; provided that the gross margin percentage of Pump
Products, in aggregate, sold by Animas Group after the increased royalties does not
fall below customary gross margin percentages for manufacturers in the med-tech
industry that provide similar levels of customer service, have similar mix of direct
versus indirect sales, and perform similar levels of R&D activities. Following any
Change of Control, the correction factor shall apply without regard to its impact on
gross margin. If the parties are unable to agree on a correction, either party may
require that the matter be determined by binding baseball arbitration pursuant to
Section 16.2 of this Agreement.

4.4 Royalties reduction. During the Royalties Term, if none of the Licensed
Patents covering any Pump Product is Valid in any Major Country, the royalty rate as
set forth in Exhibit H shall be reduced to ****** of such rate in those countries in
which Pump Products are sold, but Licensed Patents are not Valid; provided that such
reduction in royalty rates shall only occur if (i) there is another competing pump
product utilizing MEMS pump technology being sold in such country and, (ii) the Pump
Products sold in such country are not manufactured in a country where a Licensed Patent
covering any Pump Product is Valid.

4.5 Quarterly Calculation and Payment of Royalties. Royalties shall be due and
payable with respect to the Net Revenue made in each calendar quarter within 45 days
following the end of such calendar quarter ( a “Payment Date”), except for after the
fourth quarter in which case, Section 4.6 applies. On or before each Payment

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Date on which royalties are due, Animas shall prepare and deliver to Debiotech a
Quarterly Royalties Statement. The royalty rate for the second through fourth
quarters of a Year shall be determined by the applicable Patient Installed Base.
The royalty rate for the first quarter of a Year shall be provisionally calculated
based on the sum of the estimated patient installed base as of December 31 of the
prior Year plus two times the increase in patient installed base during the first
quarter of the current Year. In the event the royalty rate so determined initially
for the first quarter is different (whether higher or lower) than the royalty rate
after the second quarter of that Year, the correction shall be made to the
previously issued Quarterly Royalties Statement from the first quarter and the
difference added to or deducted from the second Quarterly Royalties Statement
prepared by Animas. Information provided to Debiotech in the Quarterly Royalties
Statement shall remain confidential and not disclosed by Debiotech to other parties.

4.6 Annual Calculation and Payment of Royalties. Within 45 days following the end
of the Year, Animas shall prepare and deliver to Debiotech an Annual Royalties
Statement, applying the royalty rate applicable pursuant to the Patient Installed Base
of that Year, subject to modifications as set forth in Sections 4.2-4.4. Information
provided to Debiotech in the Annual Royalties Statement shall remain confidential and
not disclosed by Debiotech to other parties.

4.7 Records and Audits. Licensees shall maintain detailed books and records
containing information sufficient to verify the completeness and accuracy of the
information presented in each Royalty Statement for a period of at least five years
after the period to which such Royalty Statement relates.

Debiotech shall have the right, not more than once each Year, on reasonable advance
notice to Animas, during usual business hours, to cause the examination of relevant
records of Licensees for the period since the last period covered by any previous
examination (including records which are more than five years old, if then
available) and ending with the calendar quarter covered by the most recent Payment
Date for the sole purpose of verifying the completeness and accuracy of the
Quarterly Royalty Statements and Annual Royalty Statements, including any specific
calculation relevant under this Agreement (such as with regard to Sections 3.6, 4.3
and 15.1(c)(ii)of this Agreement). At Debiotech’s election, any such examination
shall be conducted by Animas’s auditors, if allowed by law and agreeable to such
auditors, or by independent public accountants selected by Debiotech and reasonably
acceptable to Animas.

As a condition to such examination, Animas may require such independent public
accountants to execute a confidentiality agreement in form and substance reasonably
satisfactory to Animas pursuant to which such independent public accountants will
agree to retain in confidence all information learned by them in the course of such

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

examination, except that any discrepancy in any information included in a Quarterly
Royalty Statement or an Annual Royalty Statement, or being a relevant information
under this Agreement, may be disclosed to Debiotech.

Debiotech shall pay the costs of conducting such audit unless the final results of
an audit reveal an underpayment by Animas of five percent (5%) or more during the
audited period, in which case Animas shall pay the costs of conducting such audit.

4.8 Duration. Royalties are to be paid on the sale of all Pump Products sold by
Licensees throughout the world during the Royalties Term. Following the Royalties
Term, the provisions of Section 2.2 of this Agreement shall apply.

5. The Development Program and Debiotech Pump System.

5.1 Responsibilities of Debiotech. Debiotech shall use reasonable commercial
efforts to complete the Development Program (including without limitation the MEMS Pump
and the Filling System) and provide to Animas, in accordance with the milestones set
forth in Exhibit B, fully functional prototypes of (a) the MEMS Pump, including MEMS
Chip, and (b) Pump Accessories (except for the Infusion Accessories). Such prototypes
shall (i) meet the Specifications, (ii) be sufficient for FDA Submission, and (iii) be
in a form which permits redesign for manufacturing and scaling up for large scale
industrial manufacturing. Debiotech shall furnish to Animas and any manufacturer
designated by Animas all documentation necessary for the redesign for manufacturing of
the Pump Products. Debiotech shall cooperate with such designated manufacturer to
assist in any redesign necessary for manufacturing Pump Products.

To the extent that such prototypes of the MEMS Pump fail to meet the requirements
set forth above (and on Exhibit B), Debiotech shall, at its sole expense, use
reasonable commercial efforts to continue development work to satisfy such
requirements; provided that Debiotech shall not be required to continue development
if Animas has commenced marketing of the Debiotech Pump.

Without limiting Debiotech’s ability to demonstrate how it uses reasonable
commercial efforts, Debiotech shall in any event be deemed to use reasonable
commercial efforts to fulfill its responsibilities under this Section 5.1 to the
extent Debiotech’s efforts represent at least ****** in average each Year during 3
Years following Agreement Date in global development costs, including investments
costs, consulting and external development costs and internal engineering costs
calculated based upon rates provided in Exhibit C.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

5.2 Responsibilities of Animas. Animas shall use reasonable commercial efforts to
complete the Development Program (including without limitation the Pump Controller and
the Infusion Accessories) and provide, in accordance with the milestones set forth in
Exhibit B, fully functional examples of the Pump Controller and Infusion Accessories.
The Pump Controller and Infusion Accessories shall (i) meet the Specifications, (ii) be
sufficient for FDA Submission, and (iii) be in a form which permits redesign for
manufacturing and scaling up for large scale industrial manufacturing.

Animas shall be responsible for establishing the large scale manufacturing and
Debiotech shall propose appropriate materials to be used to manufacture the MEMS
Pump and Filling System and shall assist by supplying engineering support necessary
to facilitate production of the Debiotech Pump System in large scale by Animas or
suppliers designated by Animas.

5.3 Development Expenses. Each party shall be responsible for bearing its own
costs of the Development Program. Debiotech shall be solely responsible for all
expenditures of any nature required to complete the development of (a) the MEMS Pump,
including MEMS Chip, and (b) Pump Accessories (except for the Infusion Accessories) in
a form which in fact permits scaling up for large scale industrial manufacturing and
which satisfies the requirements set forth in 5.1 above. Animas shall be solely
responsible for all expenditures of any nature required to complete the development of
the Pump Controller and Infusion Accessories in a form which in fact permits scaling up
for large scale industrial manufacturing and which satisfies the requirements set forth
in 5.2 above. Animas shall be responsible for the costs of any tooling and equipment
for manufacturing of the Debiotech Pump System as well as for the cost of all required
redesign for manufacturing.

Animas agrees to spend not less than ****** to develop Debiotech Pump System prior
to January 2007 unless both parties agree, in good faith, that the Debiotech Pump
System is not feasible as a commercial product.

5.4 Reports. Debiotech shall keep Animas fully informed with regard to the
progress of the development of the Debiotech Pump System.

Not later than fifteen (15) days prior to the meetings with CEOs contemplated by
Section 5.5, Debiotech shall submit to Animas a written report including all
information regarding progress on the Development Program, disclosing any inventions
or other improvements in technology, whether or not patentable, discovered or
created in the course of the Development Program. The reports will also include a
confirmation from Debiotech that Debiotech believes that the

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Development Program can be completed consistent with the schedule contemplated by
Exhibit B, or Debiotech shall submit to Animas a revised schedule setting forth the
revised estimated time to complete the Development Program.

If reasonably necessary in addition to the above, and to the extent it would not be
unreasonably burdensome on Debiotech, upon request from Animas, Debiotech shall
allow Animas’ representatives and, where Animas shows a reasonable business purpose,
third party guests (subject to appropriate confidentiality agreements with
Debiotech), to visit the development facilities where the Development Program is
conducted, to attend presentations by Debiotech representatives of the current state
of the Development Program and to receive additional written reports addressing
specific issues.

5.5 Program Management. Each party shall appoint three senior employees, but not
their CEOs, to form the Steering Group, which shall review all the developmental,
logistical and technical aspects of the Development Program. In addition, major
financial issues shall be discussed when they arise.

At least two members of the Steering Group from each side shall meet in person at
least once every two months. Each party may invite additional participants from its
own party to attend. Minutes of the meetings shall be prepared by Debiotech,
indicating, in particular, the steps believed to be satisfactorily performed by the
parties and the next steps to be performed. Minutes shall be reviewed and approved
or rejected and amended at the next meeting of the Steering Group. Minutes of the
Steering Group shall not constitute amendments of this Agreement or the
Specifications even if signed by representatives of the parties or the CEOs of each
Party.

The Steering Group shall be charged with managing the Development Program with a
view to completing development of the Debiotech Pump System as rapidly as possible.
In addition, the Steering Group shall insure that such development be completed in
accordance with the Specifications and that the manufacturing cost of the Debiotech
Pump System be consistent with the levels set forth in the Specifications. The
Steering Group shall make recommendations to either Party regarding design and
engineering issues and shall make recommendations to Animas regarding the most
appropriate supplier(s) to manufacture the Debiotech Pump System or any part
thereof. Debiotech employees shall be primarily responsible for issues relating to
design, engineering and intellectual property with regard to the MEMS Pump and Pump
Accessories (excluding Infusion Accessories). Animas employees shall be primarily
responsible for issues relating to design, engineering and intellectual property
with regard to the Pump Controller and Infusion Accessories as well as manufacturing
and selection of suppliers. Animas shall also be responsible

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

for facilitating any incorporation of Animas’ technology, if any, in the Debiotech
Pump System.

Either Party’s members on the Steering Group may recommend modifications to the
Specifications and the Development Program by submitting a written request to the
other Party’s members on the Steering Group detailing the nature of the
modification, the reason for the modification and the anticipated costs associated
with implementing the modification. Any modification must be approved in writing by
each Party’s CEO. Each Party agrees not to unreasonably withhold their approval to
a modification suggested by the other Party so long as the consenting Party cannot
demonstrate with written documentation that the modification (i) materially
adversely affect the marketability and desirability of the Debiotech Pump System,
(ii) materially affects the cost of the development effort, or (iii) materially
affects the timing of the availability on the market of the Debiotech Pump System.

Each Party’s members on the Steering Group shall keep their respective CEOs
informed as necessary. The Steering Group shall meet in person with the CEOs as a
group of eight at least once every 4 months. The Steering Group shall attempt to
resolve issues without the involvement of the CEOs; provided that, in the event the
parties cannot agree, the issue shall be put before the CEOs who shall use
commercially reasonable efforts to resolve the issue.

Meetings of the Steering Group (other than those to attended by the CEOs) shall
be held at the location where the most active development work is being conducted,
which the parties anticipate will be in Lausanne Switzerland through the early and
middle stages of the Development Program, and may be the site of anticipated
manufacturing facilities later in the Development Program. Meetings of the Steering
Group attended by the CEOs shall alternate between locations designated by the CEO
of Animas and the CEO of Debiotech.

5.6 Obligations to develop Product. Debiotech agrees that it will devote the
resources as reasonably necessary to ensure development of the MEMS Chip and Pump
Accessories (excluding the Infusion Accessories) by June 30, 2007. In the event
Debiotech is not successful in developing the MEMS Chip and Pump Accessories (excluding
the Infusion Accessories) by June 30, 2007, Animas may terminate this Agreement in
accordance with Section 15.1(c) of this Agreement or, Animas may, in its sole
discretion, extend the Development Program by up to an additional eighteen (18) months;
provided, however, the June 30, 2007 date shall be extended (i) for such number of days
as the Steering Group agrees to extend the Development Program in accordance with
Section 5.5, and/or (ii) for each day that the development of the Pump Controllers
and/or Infusion Accessories in accordance with the Development Program is delayed by
Animas.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Animas agrees that it will devote the resources as reasonably necessary to ensure
development of the Pump Controller and Infusion Accessories in time for Debiotech to
complete the Development Program by June 30, 2007.

5.7 Failure to complete Development Program. Because of the uncertainties
associated with the development work, neither party warrants that it will successfully
complete the Development Program.

5.8 Choice of Suppliers under Development Program. Debiotech and Animas must
jointly agree on choice of suppliers for any part or process of the Development Program
if Non-recurring Engineering Expense (NRE) or tooling charge exceeds $20,000.

6. Regulatory Responsibility.

6.1 Regulatory Filings. Animas shall use commercially reasonable efforts to file
regulatory approvals, including to the FDA, pending completion of test results and
other documentation required for such submission.

6.2 Documentation for regulatory submission. In connection with preparation by
Animas of the FDA Submission and during the review by FDA of the FDA Submission,
Debiotech shall: a) furnish all test results and documentation on MEMS Pump and Pump
Accessories (except for Infusion Accessories) required by FDA and, b) remain available
for responding to questions by FDA relating to such FDA Submission.

6.3 Clinical Studies. Animas shall be responsible for oversight of clinical
studies, if any, necessary to obtain FDA Approval, and shall be responsible for the
cost of any such studies. Protocol of clinical studies must be approved by Debiotech
in advance.

6.4 Material for Clinical Studies. Notwithstanding the provisions of Section 7.1
of this Agreement, Debiotech shall furnish MEMS Pumps and related Pump Accessories
(except Infusion Accessories which shall be supplied by Animas), in accordance with
Specifications, needed for clinical studies as required in Section 6.3 of this
Agreement, provided that ****** MEMS Pumps and related Pump Accessories
shall be delivered. The cost of all such deliverables shall be borne solely by
Debiotech, provided that, Animas shall be responsible for any investments necessary for
manufacturing and redesign for manufacturing, to the extent required.

6.5 Regulatory Obligations. Animas and Debiotech shall cooperate in the
preparation of, and shall execute, as part of the Development Program, a Quality
Agreement in order

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

to meet the requirements of ISO13485, European MDD and FDA QSR (21 CFR 820)
requirements for medical devices, to the extent applicable.

7. Manufacturing Program of MEMS Chip.

7.1 Manufacturing Responsibility. Animas shall be responsible for all aspects of
manufacturing of Pump Products, and shall bear all corresponding costs, except to the
extent specifically stated otherwise.

7.2 Choice of Initial Manufacturer. Debiotech shall recommend not less than three
candidates of initial manufacturer for the MEMS Chip. Animas may choose between one of
three candidates to be the initial manufacturer. If for whatever reason, Animas finds
the three candidates unacceptable, Animas may recommend other candidates, whose
endorsement by Debiotech may not be unreasonably withheld.

7.3 Debiotech Assistance. Debiotech, at its own cost, shall provide (i) all
documentation of all processes, materials, testing, and assembly instructions necessary
for the initial manufacturer to manufacture the MEMS Chip in small-scale manufacturing
and further enter into a redesign for manufacturing for large-scale production, (ii)
any training required of personnel of the initial manufacturer to manufacture the MEMS
Chip, (iii) any additional technical support including for re-design/ revalidation of
processes necessary for large-scale manufacturing ((i) to (iii) constituting the
Manufacturing Program), and (iv) continued technical support including for
re-design/revalidation of processes, until the initial manufacturer has delivered to
Animas ****** MEMS Chips to be placed on the market.

7.4 Cost. The cost of all required manufacturing tools and equipments as well as
for the redesign for manufacturing shall be borne by Animas.

7.5 Support after Manufacturing Program. Debiotech shall provide employees as
reasonably requested by Animas from time to time to support manufacturing and technical
issues, as they may arise of MEMS Pump after completion of Manufacturing Program.
Animas shall reimburse Debiotech at rates as provided for in Exhibit C, plus
out-of-pocket expenses.

7.6 Access to MEMS Chip and MEMS Pump Manufacturer. Subject to the terms and
conditions of this Section 7.6 and Section 12.1 of this Agreement, Debiotech shall have
the right to buy directly from the manufacturer (the “MEMS Manufacturer”) the MEMS
Chips and/or MEMS Pump used in the Debiotech Pump for use outside the Field.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

To the extent Debiotech requires MEMS Manufacturer to use substantially the same
tooling and equipment which is either (a) used by and has been specifically paid for
by Animas, or (b) is owned by Animas (the “Tooling”), then (i) Debiotech must
reimburse Animas for its pro rata share of any non-recurring engineering costs
(excluding Animas personnel) and tooling costs incurred by Animas for the
manufacture of such MEMS Chips and/or MEMS Pump, irrespective of when such costs
were incurred (provided such reimbursement shall not apply to prototypes and ******
in an amount less than ****** requested by Debiotech for development, clinical
evaluation and registration purposes so long as the manufacture of such prototypes
and small series do not cause delays to Animas deliveries); (ii) Animas shall have
priority in the supply of MEMS Chips over Debiotech in the event that the MEMS
Manufacturer is unable to provide all quantities of MEMS Chips requested by both
Debiotech and Animas unless Animas has failed to provide MEMS Manufacturer an
adequate forecast of such requirements as set forth in the agreement between the
MEMS Manufacturer and Animas; (iii) any request for a change by Debiotech in the
design or manufacturing of Tooling must be approved by Animas prior to any
discussion with MEMS Manufacturer, and further any such discussions between MEMS
Manufacturer and Debiotech, after such approval by Animas for such discussions, may
only be done in the presence of Animas personnel; and (iv) in no case, may any
change in the design or manufacturing of such Tooling be made without the explicit
approval in writing by Animas, and further Animas is under no obligation to approve
a change in the design or manufacture of such Tooling, even if Debiotech believes
that Animas is unreasonably withholding its approval.

All rights and obligations of Debiotech in this Section 7.6 shall inure to
Debiotech’s licensees outside the Field, provided that, such licensees agree to
indemnify Animas from any third party claims in connection with their use of the
Tooling as per this Section 7.6, and further provided, that the prior written
approval by Animas is obtained, which approval shall not be unreasonably withheld.
Debiotech shall indemnify and hold harmless Animas, its successors and assigns,
Affiliates, and their respective agents, officers, employees, representatives and
directors from any third party claims in connection with Debiotech using the Tooling
as per this Section 7.6. In the event Debiotech or its licensees sell product in
the Field in a manner which is under the reasonable control of Debiotech or its
licensee, in addition to any remedies that may exist under this Agreement, all
rights of Debiotech under this Section 7.6 may be terminated, provided (i) sales
were made willfully in the Field, or (ii) sales were made negligently in the Field
and are materially harmful to Animas. Such termination rights shall not apply to
the extent Debiotech or its licensee, following notice from Animas, fails to cure
the breach within ******.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

8. Representations, Warranties and Covenants.

8.1 Authorization. Each party represents that it is duly organized, validly
existing and in good standing under the laws of the state of its organization, that it
has full power to execute, deliver and perform this Agreement, that this Agreement has
been duly authorized, executed and delivered by such party and is the legal, valid and
binding obligation of such party, enforceable against such party in accordance with its
terms, subject as to enforcement, to applicable bankruptcy, insolvency, moratorium,
reorganization or similar laws affecting creditors’ rights generally and general
principles of equity.

8.2 No Conflict. Each party represents that the execution, delivery and
performance of this Agreement do not require any approval, license, qualification,
consent or filing or exemption therefrom, or other action by any court, governmental
authority or other person, and do not contravene or constitute a default under any
legal requirement binding on such party, any agreement binding on such party or any of
its assets, or any judgment, injunction or order or decree binding on such party or any
of its properties. In particular, Debiotech represents that its agreement with
Inverness Medical Technology and its successor has been terminated as of January 18,
2004 and Inverness does not retain any rights to any Debiotech Intellectual Property
under such agreement.

8.3 No Litigation. Each Party represents that there is no actual, pending or, to
the best knowledge of such Party, threatened action, suit, proceeding or investigation
against or affecting it or any of its assets (including, with respect to Debiotech,
Debiotech Intellectual Property and, with respect to Animas, the License Shares) before
or by any court or arbiter or any governmental authority which would prohibit or
interfere with such Party performance of its duties under this Agreement.

8.4 No Intellectual Property of Third Parties. Debiotech represents that, to the
best knowledge of Debiotech, there is no Valid intellectual property owned by any third
party which would restrict Animas from making, using and selling Debiotech Pump System
(as defined in the Specifications) in the Field throughout the world under the License
in accordance with the terms of this Agreement without payment to third parties.
Debiotech further warrants that it has not received any communication from third
parties (i) notifying it that the Debiotech Pump System might infringe intellectual
property rights of any third party, or (ii) questioning the ability of Debiotech
Intellectual Property to adequately prevent third parties from duplicating the
Debiotech Pump System without infringing.

8.5 Ownership of Intellectual Property. Debiotech represents that it owns (whether
by ownership directly or through licensed rights) the Licensed Patents described in
Exhibit A, free and clear of any claims of any third party. Debiotech represents that,

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

to the best knowledge of Debiotech, it owns (whether by ownership directly or
through licensed rights) all of the intellectual property necessary or useful for
the development of the Debiotech Pump System under the Development Program,
including without limitation, the Debiotech Intellectual Property, free and clear of
any claims of any third party. Debiotech represents (i) that, to the best knowledge
of Debiotech, none of such intellectual property infringes or misappropriates any
intellectual property rights or other property rights of any third party other than
third parties identified in (v) below that have licensed relevant technology to
Debiotech; (ii) that no intentional misrepresentations were made in any applications
for patents included within Debiotech Intellectual Property; (iii) that all such
patent applications have been made in good faith; (iv) that Debiotech does not have
any knowledge of any factors which would compromise the validity of any of the
Licensed Patents; and (v) that, to the best knowledge of Debiotech, with exception
of the license dated August 1992 from ****** to Debiotech (the “****** License”) and
the ****** License, Debiotech does not possess, nor does it currently require, any
other third party license(s) to make, sell, use and/or import the Debiotech Pump.

8.6 Authorization to License. Debiotech represents that Debiotech is legally
authorized to license, on a worldwide basis, all Licensed Patents, including those
identified as “****** patents” and covenants to protect Animas from any recourse made
by ****** (the patents assignee) as evidenced by the estoppel letter described in
Section 8.7 of this Agreement. Debiotech also represents that it is legally authorized
to sub-license, on a worldwide non-exclusive basis, the ****** License.

8.7 ****** Intellectual Property. Debiotech, at its sole expense, shall arrange for
Animas to receive an estoppel letter, in form and substance reasonably satisfactory to
Animas, from the owner of the intellectual property licensed to Debiotech under the
****** License, confirming, among other things, that Animas may use the License without
obligation to pay any royalties to ****** or any third party and that such owners will
look solely to Debiotech for payment of any royalties owing to them as a result of
Animas’ exploitation of the License.

8.8 License under Future Patents. Debiotech represents and covenants that Animas
shall be granted exclusive worldwide license rights, under any future patents of
Debiotech (in furtherance of Sections 13.1 and 13.2 of this Agreement) or of ****** to
the extent such future patents are included within Debiotech Intellectual Property for
use in the Field.

8.9 Feasibility of Development Program. Debiotech represents that it reasonably
believes that the Development Program can be successfully completed within the
timeframes set forth in this Agreement and the manufacturing costs set forth in Exhibit
B.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

8.10 Data. Debiotech represents that all test data presented to Animas during the
due diligence are correct, accurate and true.

8.11 Indemnification. Debiotech shall indemnify, defend and hold harmless
Licensees, their respective successors and assigns, and their respective agents,
officers, employees, representatives and directors from and against claims made against
them by third parties, including any and all actions, suits, damages, claims, loss or
liabilities (including, without limitation, reasonable attorneys’ fees and costs of
collection) arising out of or caused by a breach by Debiotech of any of its
representations made in this Article 8. Notwithstanding the foregoing, Debiotech’s
indemnification obligations set forth in this Section shall not apply with respect to
any claims by Licensees that Debiotech Intellectual Property infringes the intellectual
property of such Licensee.

Licensee shall promptly notify Debiotech of such claim. Debiotech shall have the
right to assume and control the defense, direct the investigation, and control the
settlement of each such claim, provided that, Debiotech shall not settle the claim
or otherwise consent to a judgment relating to such claim without the prior written
consent of the Licensee (such consent not to be unreasonably withheld or delayed).
Licensee shall be permitted to participate to any proceedings at its own expense.

Debiotech and Licensee shall fully cooperate with each other in connection with the
defense of such claim, including by furnishing all available documentary or other
evidence as is reasonably requested by the other.

If Debiotech elects not to settle or defend such claim, the Licensee shall (at the
expense of Debiotech) have the right to assume the defense of such claim and shall
have the right to settle (with the prior written consent of Debiotech, such consent
not to be unreasonably withheld or delayed).

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

9. Limitations of Liability

	 	9.1  	EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR WARRANTIES, ORAL OR WRITTEN, EXPRESS OR IMPLIED, ARISING FROM COURSE
OF DEALING, COUSE OF PERFORMANCE, USAGE OF TRADE, OR OTHERWISE, INCLUDING IMPLIED
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR TITLE.
	 
	 	9.2  	EACH PARTY’S TOTAL AGGREGATE LIABILITY FOR DAMAGES UNDER THIS AGREEMENT SHALL
UNDER NO CIRCUMSTANCES EXCEED $ 5 MILLION, EXCEPT AS PROVIDED BELOW (PROVIDED THAT
DEBIOTECH’S LIABILITY FOR DAMAGES SHALL BE REDUCED TO $ 1.5 MILLION IF ANIMAS RECOVERS
THE TERMINATION PAYMENT PURSUANT TO SECTION 15.1(C) OF THIS AGREEMENT). UNDER NO
CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ANY OTHER PERSON FOR LOST
REVENUES, LOST PROFITS, LOSS OF BUSINESS, OR ANY INCIDENTAL, INDIRECT, EXEMPLARY,
CONSEQUENTIAL, SPECIAL, OR PUNITIVE DAMAGES OF ANY KIND, WHETHER OR NOT FORESEEABLE,
EVEN IF ONE PARTY HAS BEEN ADVISED OR WAS AWARE OF THE POSSIBILITY OF SUCH LOSS OR
DAMAGE. THE FOREGOING LIMITATIONS SET FORTH IN THE TWO PREVIOUS SENTENCES SHALL NOT
APPLY WITH RESPECT TO (i) EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS
AGREEMENT, (ii) BREACHES BY EITHER PARTY OF THE OTHER PARTY’S INTELLECTUAL PROPERTY
RIGHTS, (iii) BREACHES BY DEBIOTECH OF THE LICENSE GRANTED ANIMAS IN THIS AGREEMENT,
(iv) BREACHES BY ANIMAS OF SECTION 2.4 OF THIS AGREEMENT, OR (v) FRAUDULENT
MISREPRESENTATIONS.
	 
	 	9.3  	The representations made by each Party under this Agreement and the obligations
of each Party under this Agreement, run only to the other Party, and not to any
Affiliate, sublicensee, customer or any other Person. Under no circumstances shall any
Affiliate of the other Party, its customers, or any other Person be considered a third
party beneficiary of this Agreement or otherwise entitled to any rights or remedies
under this Agreement.

10. Lawsuits by Others Alleging Infringement of Debiotech Pump.

10.1 Infringement Claims by Third Parties. In the event that a third party, other
than a Licensee, asserts any claim or cause of action alleging that the Debiotech Pump
System (i) infringes of a patent or copyright of another person, or (ii) unlawfully

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

discloses or uses or misappropriates a trade secret or other intellectual property
right of a third person, Animas shall have the right to assume control and direct
the investigation, defense and settlement of each such claim.

Animas shall keep Debiotech fully informed of all developments of the case,
including any counterclaims made by Animas. Animas shall, to the extent legally
permissible and without waiving attorney client privilege, (a) provide Debiotech
with copies of all pleadings, discoveries and other relevant material (including
discussion papers, submissions, opinions, technical evaluations, expert or witness
statements and any other material contemplated to be used in the proceedings or
otherwise relevant to the proceedings, whether in draft or final form), and (b)
allow, except to the extent it would prove impracticable, participation in defense
strategy discussions; provided that, Debiotech shall agree to appropriate
confidentiality undertakings. Debiotech and its agents, representatives and
employees shall at all times have the right, at its own cost, to participate in the
defense (and assume the defense if Animas does not act in good faith in defending
the claim).

The Parties shall fully cooperate with each other in connection with the defense of
such claim, including by furnishing all available documentary or other evidence as
is reasonably requested by the other.

Animas shall not, to the extent reasonably practicable, settle the claim or
otherwise consent to an adverse judgment in such claim without the express written
consent of Debiotech, which consent shall not be unreasonably withheld or delayed.
In the event that Debiotech reasonably withholds its consent, whether such consent
is requested before or after the settlement is reached, the provisions of Section
10.3 of this Agreement shall not apply.

10.2 Claims by Licensees. In the event that a Licensee asserts any claim or cause
of action for patent or copyright infringement, unlawful disclosure or use or
misappropriation of a trade secret or other intellectual property right against another
Licensee or Debiotech in connection with the Debiotech Pump System, Animas shall be
solely responsible in connection with such claim and the provisions of Section 10.3
shall not apply.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

10.3 Royalty Offset. Subject to the limitations below in this Section 10.3,
Debiotech shall reimburse Animas for the lesser of (i) ****** of all license fees,
costs, settlement fees, expenses, damages and liabilities, including reasonable counsel
fees and expenses , incurred by Licensees as a result of any third party claim under
Section 10.1 of this Agreement and (ii) ****** of the aggregate royalties received
pursuant to Article 4 and of the estimated future royalties to be received of the date
of the assessment of such Infringement Costs. Such payment shall be referred to as an
“Infringement Payment” and shall be credited in full against ****** of all royalties
falling due to Debiotech under this Agreement thereafter. Debiotech shall have no
obligation to make an Infringement Payment if the claims are based on technology
sourced from or developed by Licensees (including Pump Controller and Infusion Sets
sourced or developed by Animas). To the extent the Parties resolve differences
regarding this Section 10.3, the Parties shall submit the matter to baseball
arbitration pursuant to Section 16.2 of this Agreement.

10.4 Cooperation. If, prior to Commercial Launch, either party finds intellectual
property of a third party that could potentially prevent or restrict commercialization
of the Debiotech Pump System in accordance with the Specifications, the parties shall
work together to develop an alternate design or a solution not to infringe the third
party intellectual property rights.

11. Product Liability.

11.1 Indemnification by Animas. Animas shall indemnify, defend and hold harmless
Debiotech, its agents, officers, employees, representatives and directors from and
against any and all third party actions, suits, damages, claims, losses or liabilities
(including, without limitation, reasonable attorneys’ fees and costs of collection)
arising out of or caused by an allegedly defective product. Animas shall have no
obligation under this Section 11.1 to the extent such claim arises out of or is caused
by the dishonesty or wanton carelessness of Debiotech.

Debiotech shall promptly notify Animas of such claim. Animas shall have the right
to assume and control the defense, direct the investigation, and control the
settlement of each such claim. Debiotech shall be permitted to participate to any
proceedings at its own expense.

The Parties shall fully cooperate with each other in connection with the defense of
such claim, including by furnishing all available documentary or other evidence as
is reasonably requested by the other.

If Animas elects not to settle or defend such claim, Debiotech shall (at the expense
of Animas) have the right to assume the defense of such claim and shall have the
right to

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

settle (with the prior written consent of Animas, such consent not to be
unreasonably withheld or delayed).

     11.2 Insurance Requirements.

Animas agrees that it will maintain the levels of insurance it has as of the
Agreement Date and Debiotech agrees (except to the extent that purchasing such
levels of insurance would be unreasonable from a commercial point of view ) that it
will maintain at least ****** in insurance coverage, in each case at such party’s
sole cost and expense. Commencing with the clinical testing of the Debiotech Pump
on human patients, Animas agrees to maintain in effect and deliver to Debiotech a
certificate regarding a comprehensive general liability insurance in which Debiotech
is an additional insured in an aggregate amount of at least ******, except to the
extent that purchasing such levels of insurance would be unreasonable from a
commercial point of view.

12. Indemnification by Debiotech Outside Scope of this Agreement.

	 	12.1  	Notwithstanding the provisions of Sections 10.1 and 11.1 of this Agreement,
Animas shall have no obligation to defend or indemnify Debiotech, Debiotech’s
sub-licensees or any third party and Debiotech shall indemnify and hold harmless
Licensees, their respective successors and assigns and their respective agents,
representatives, officers, directors and employees from and against claims made against
them by third parties, including any and all actions, suits, claims, losses, damages,
costs and expenses, arising out of or caused by (i) the licensing by Debiotech of
Debiotech Intellectual Property to third parties, (ii) the licensing of jointly
developed intellectual property to third parties, or (iii) any use by Debiotech and
Debiotech’s sub-licensees of the Debiotech Intellectual property, any jointly developed
intellectual property by Debiotech, or any future inventions outside the Field of Use.
For the avoidance of doubt, liabilities include, but are not limited to: (x) any
product liability or other claim of any kind related to use by a third party of
Debiotech Intellectual Property or any jointly developed intellectual property; (y) a
claim by a third party that the Debiotech Intellectual Property or jointly developed
intellectual property infringes or violates any patent, copyright, trade secret,
trademark or other intellectual property right of such third party; and (z) claims
arising from clinical trials or studies conducted by or on behalf of Debiotech, its
Affiliates, sublicensees, assignees or vendors or third parties relating to the
Debiotech Intellectual Property or jointly developed intellectual property rights, such
as claims by or on behalf of a human subject of any such trial or study.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

13. Ownership of Inventions and Protection of Trade Secrets.

13.1 Future Inventions. Inventions made by Debiotech employees and consultants
shall be the sole property of Debiotech. Such inventions made during the Royalties Term
shall be included within Debiotech Intellectual Property, so as to subject them to the
License, with no additional consideration payable by any Licensee.

Inventions made by Animas Group employees and consultants shall be the sole property
of Animas Group. Animas hereby grants to Debiotech a royalty-free exclusive
worldwide license for use outside of the Field, including the right to sublicense,
under any such invention made during the Royalties Term specifically relating to the
design or manufacture MEMS chips, but no license is granted to inventions relating
to micro-pumps irrespective of whether or not such micro-pumps utilize a MEMS Chip.

Inventions made by employees and consultants of both Animas Group and Debiotech
shall be the joint property of both parties with such inventions being part of the
Licensed Patents, Animas Group having an exclusive right, even as to Debiotech, to
such joint inventions in the Field with no further consideration, and Debiotech
having an exclusive right, even as to Animas Group, to such joint inventions for use
outside of Field worldwide with no further consideration. If such joint invention
specifically involves MEMS technology, Debiotech shall be responsible for
prosecution and maintenance of patents; otherwise Animas shall be responsible for
prosecution and maintenance of patent.

13.2 Future Developments of IP. Debiotech shall keep Animas regularly informed of
any future development of the MEMS Pump made by Debiotech during the Royalties Term and
such development shall be included in Debiotech Intellectual Property so as to subject
such development to the License, with no additional consideration payable by Licensees.
However, to the extent such future development is requested by Animas, Animas shall
reimburse Debiotech at rates as provided for in Exhibit C for the actual cost incurred
to develop such future development to the extent such development is beyond the
parameters and scope of Exhibit B or the costs necessary to transfer the technology
requested by Animas.

Animas shall keep Debiotech informed of (i) any developments to the MEMS Pump made
by Animas Group employees and consultants during the Royalties Term and (ii) any
developments to the then current manufacturing processes made during the Royalties
Term. Debiotech shall have non-exclusive rights outside of the Field to use any
developments of the MEMS Pump made by Animas Group during the Royalties Term, with
the right to sublicense. The rights of Debiotech set forth in this paragraph shall
be referred to as “Section 13.2 Rights”.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

13.3 New Technology. Provided that no Change of Control has occurred, Debiotech
shall give Animas a right of first refusal with regard to any proposed license or
transfer of rights by Debiotech to any new technology in the Field (not included within
Debiotech Intellectual Property as Animas already has exclusive rights to the Debiotech
Intellectual Property) (“Transfer”) on terms at least as favorable as those offered to
any third party, if applicable. Notwithstanding the foregoing, such right of first
refusal shall not apply to the extent any Transfer is solely related to a
reorganization of Debiotech, the end result of which (after the closing of all such
transactions) is no change in the ultimate ownership or control of such new technology.

               (a) Notice. Debiotech shall provide Animas with written notice of a
Transfer opportunity. Such notice shall include the terms of the proposed Transfer,
including proposed scope, consideration, and other material terms, but not the third
party with whom a Transfer would be contemplated (the “ROFR Notice”).

               (b) Animas Answer. Animas shall respond to Debiotech within thirty
(30) days following receipt of the ROFR Notice, indicating either (i) declination of
the proposed Transfer; or (ii) Animas’s interest to the proposed Transfer on the
material terms contained in the ROFR Notice. In the event that Animas fails to
provide Debiotech with written notice of any kind, such silence shall be deemed a
declination of the proposed Transfer.

               (c) Negotiations. Animas and Debiotech shall, for a period not less
than forty-five (45) days from Debiotech’s receipt of the Animas notice indicating
interest, negotiate in good faith to reach agreement and finalize mutually
satisfactory documentation (whether a full agreement or a binding term sheet)
relating to the proposed Transfer.

               (d) Third Parties. In the event that Animas declines the proposed
Transfer, or if Debiotech and Animas cannot agree on the terms of a definitive
transaction, then Debiotech shall be allowed to enter into definitive agreements
with any third party and consummate the proposed Transfer, provided that the terms
and conditions (including financial) contained in the definitive agreement are not
less favorable to Debiotech than those contained in the latest ROFR Notice.

13.4 Application for and Prosecution of Patents. At its sole expense, Debiotech
shall diligently file, and prosecute applications for Licensed Patents in the Major
Countries, Japan and Canada (collectively, the “Group A Countries”) and in such other
countries (the “Group B Countries”) as Animas may request, and, except as provided
below in this Section 13.4, and shall maintain any patents issued thereon by payment of
all required renewal or maintenance fees or taxes. Debiotech will make all initial
Group A Country filings using a Patent Cooperative Treaty filing and will

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

use the same Patent Cooperative Treaty filing for the Group B Countries to the
extent available.

If Debiotech determines that the costs of maintaining a patent in any of the Group B
countries exceeds the value of doing so Debiotech may, not later than sixty (60)
days prior to the last date on which payment must be made to maintain the patent,
give written notice to Animas enclosing a copy of the patent, stating the amount
required to be paid periodically to maintain such patent, and offering to assign
such patent to Animas. If Animas elects to accept Debiotech’s offer to assign such
a patent, Debiotech shall execute such documentation of such assignment as Animas
may reasonably require and Animas shall grant to Debiotech a worldwide,
non-exclusive, perpetual and royalty-free license under such patent outside of the
Field. If Animas elects not to accept Debiotech’s offer to assign such patent,
Debiotech may abandon such patent.

Debiotech will interact directly with patent agents and law firms on all patent
prosecution and patent maintenance matters related to the Licensed Patents and will
copy Animas on all material correspondence related thereto. Debiotech shall
instruct the patent agents and law firms to provide Animas directly with any
information reasonably requested by Animas. With respect to any matter involving
Licensed Patents, Debiotech agrees to use all reasonable efforts to notify Animas
in writing at least thirty (30) days prior to the due date or deadline for any
action which could jeopardize maintenance of any patent in any country.

Debiotech shall inform Animas of the patent agents and law firms providing
legal services relating to the Licensed Patents and jointly developed intellectual
property which will be performed on behalf of Animas. Debiotech will authorize such
patent agents and law firms to inform Animas, at any time upon request and at the
cost of Animas, of the status of each such patent and/or patent application. The
designated patent agents and law firms shall invoice Debiotech directly for all work
relating to the filing, prosecution and maintenance of the Licensed Patents.
Debiotech is responsible for the payment of all charges and fees so invoiced by
patent agents and law firms. In the event Debiotech would fail to make the
necessary payment, Animas shall have the right to make any such payment directly to
the patent agents and law firms, which shall be off-set against any payments
otherwise due to Debiotech under this Agreement.

13.5 Infringement of Debiotech Intellectual Property. In the event that Debiotech
or a Licensee knows or suspects that a third party infringes Debiotech Intellectual
Property in the Field, it shall notify Animas or Debiotech about such infringement.

Animas may, in its sole discretion, pursue parties that it believes in good faith
infringe upon Debiotech Intellectual Property and control and direct the
investigation,

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

prosecution and settlement of each such claim. In such case, any amounts recovered
from an infringer of Debiotech Intellectual Property in the Field, including
settlements for past-infringement, damages, and judgments against the infringing
party, shall be applied first to pay or reimburse the costs incurred by Animas and
Debiotech for proceeding against such infringer, and then shall be split between the
parties, ****** for Debiotech and ****** for Animas. If Animas and infringing party
agree to sublicense of Debiotech Intellectual Property, Debiotech shall receive
****** of all sublicense fees (in accordance with Section 3.6 of this Agreement)
after reimbursement for costs incurred by Animas and Debiotech for proceeding
against such infringer, if not already paid by settlement fees, if any.

If Animas elects not to pursue such party that infringes, Debiotech may do so, at
its sole expense. In such case, any amounts recovered from an infringer of Debiotech
Intellectual Property in the Field, including settlements for past-infringement,
damages, and judgments against the infringing party, shall be applied first to pay
or reimburse the costs incurred by Debiotech and Animas for proceeding against such
infringer, and then shall paid 100% for Debiotech. If Debiotech, Animas, and
infringing party agree to sublicense Debiotech Intellectual Property to a third
party, Debiotech shall receive ****** of all sublicense fees (in derogation to
Section 3.6 of this Agreement) after reimbursement for costs incurred by Animas and
Debiotech for proceeding against such infringer, if not already paid by settlement
fees, if any.

Debiotech and Animas shall fully cooperate with each other in connection with any
such proceeding.

14. Confidentiality and Nonsolicitation.

14.1 Identified Information. For purposes of this Agreement, “Confidential
Information” shall mean information, data or material deemed proprietary by disclosing
party and which may be marked, or, if orally transmitted, designated as “Confidential”
by disclosing party and not generally known by the public. Confidential Information
also includes any information described above which disclosing party obtains from
another party and which disclosing party treats as proprietary or designates in writing
as Confidential Information, whether or not owned or developed by disclosing party.
Confidential Information includes, but is not limited to, the following types of
information and other information of a similar nature (whether or not reduced to
writing): discoveries, ideas, concepts, software in various stages of development,
techniques, models, data, documentation, user manuals, diagrams, flow charts,
consulting methods and techniques, research, development, processes, procedures,
“know-how”, marketing techniques and materials, marketing and development plans,
customer names and other information related to customers, price lists, pricing
policies and financial information, methods of production, and specialized recovery
equipment and techniques. Confidential Information shall further include data

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

regarding business practices, pricing, product philosophy, and position relative to
competitors. For the avoidance of doubt Confidential Information shall include
information deemed confidential under the confidentiality agreement between the
parties dated July 6, 2004.

14.2
  Standard of Care. Each Party will use the same efforts to protect such
Confidential Information of disclosing party as they use to protect its own proprietary
information and data. Disclosure of the Confidential Information shall be restricted
to those individuals who are participating in the proposed transaction solely on a
“need to know” basis and who are advised of this Agreement and agree to be bound by its
terms, or as otherwise may be required by law. Such obligation shall continue for so
long as disclosing party treats the Confidential Information as confidential. This
provision shall not restrict disclosure of information for the purpose of obtaining
patents or meeting regulatory requirements, or the disclosure of information otherwise
required to be disclosed by law. A recipient of information shall have no obligation
of confidentiality with respect to information that (i) was in the possession of the
recipient before receipt from the disclosing party, (ii) is or becomes publicly
available through no fault of the recipient, or (iii) is lawfully acquired by the
recipient from a third party having the right to disclose such information.

Each party shall require that its employees, agents and consultants who receive
confidential information of the other party shall not disclose such information
except as the recipient is entitled to, or to other employees, agents and
consultants of the recipient who have a need to know for a business purpose of the
recipient and are under a similar confidentiality obligation.

14.3   Disclosure of Agreement. This Agreement shall remain confidential, except
as required by law, including US securities laws. Both parties agree to make a press
release, upon signing this Agreement. Any press release or public disclosure by one
party relating to this Agreement shall require the prior consent of the other party,
not to be unreasonably withheld, except as required by law, including US securities
laws, and except to the extent such public disclosure would be limited to information
previously publicly disclosed by the other party or cleared for disclosure by the
other party, provided that, neither party shall use quoted statements of the other
without prior consent.

To the extent it is reasonably necessary for one party to give access to this
Agreement to a third party which needs it in connection with a proposed business or
legal transaction, such party shall have the right to make it available to said
third party provided a strict confidentiality agreement has been secured prior
thereto.

14.4   Nonsolicitation.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Each Party agrees that, for a period ending three (3) years after completion of the
Manufacturing Program, it will not, directly or indirectly, on its own behalf or on
behalf of any Affiliate, employ, endeavor to employ, solicit or induce to leave any
of the other Party’s management, engineers or technicians who are, or were employed
by the other party within two years prior thereto.

15. Termination and Default.

15.1 Termination by Animas.

	 	(a)  	Termination for Convenience. Animas may, at any time after the
payment to Debiotech has been made pursuant to Section 3.1 of this Agreement
and the License Shares have been delivered to Debiotech pursuant to Section 3.2
of this Agreement, give notice to Debiotech electing to terminate its rights
under the License.
	 
	 	(b)  	Default of Debiotech. If Debiotech materially breaches any
provision of this Agreement, Animas may give written notice to Debiotech
specifying the nature of such breach in reasonable detail and Debiotech shall
have ninety (90) days (after receipt of Animas’ written notice) in which to
cure such breach. Animas may terminate this Agreement immediately if such
material breach remains uncured after such ninety (90) days cure period. The
parties agree that, except in cases in which the breached obligation of
Debiotech would involve a duty to achieve a specific result, and in particular
with respect to all Debiotech’s obligations pursuant to Section 5.1 of this
Agreement, the resumption of reasonable commercial efforts and not the
achievement of any specific result by Debiotech shall be deemed to be a cure by
Debiotech.

For the avoidance of doubt, the parties acknowledge that if Debiotech is in
default under this Agreement, Animas may seek all remedies available to it under
this Agreement or under the governing law (subject to the limitations contained
in this Agreement), including, without limitation, submitting the matter to the
arbitration provisions of Section 16.1, and is not required to terminate this
Agreement.

	 	(c)  	Termination with Termination Payment. Provided a Change of
Control has not occurred, Animas may terminate this Agreement in the event (i)
Debiotech is not successful, despite using reasonable commercial efforts, in
developing the MEMS Pump, including MEMS Chip, and Pump Accessories (except for
the Infusion Accessories) according to the Specifications by ****** (or such
extension date as provided in Section 5.6 of this Agreement), or (ii) ****** have not been sold or placed to end-users within ******
following Commercial Launch (provided Animas may terminate only as long as

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

****** have not yet been placed). If Animas terminates this Agreement
pursuant to this Section 15.1(c), the termination payment set forth in Section
15.3 (b) of this Agreement will be payable by Debiotech. Such termination right
and termination payment shall be Animas’ sole remedy and such termination
payment, or a portion thereof, shall not be due to the extent Animas has
recovered damages under Section 9.2 of this Agreement.

	 	(d)  	Termination for Bankruptcy. If Debiotech is adjudicated
bankrupt, if bankruptcy, insolvency, reorganization, debt adjustment or
liquidation proceedings, including an involuntary proceeding, are instituted
against Debiotech and not dismissed within one hundred eighty (180) days after
the institution thereof, if a receiver or trustee is appointed for Debiotech
and its assets, or if Debiotech makes a general assignment for the benefit of
its creditors, Animas may terminate this Agreement immediately.

15.2 Termination by Debiotech

	 	(a)  	Termination for Payment Default by Animas. If Animas fails to
make the payment required by Section 3.1 of this Agreement or fails to deliver
the License Shares required by Section 3.2 of this Agreement, Debiotech may
give written notice to Animas specifying the default and Animas shall have
fifteen (15) days in which to cure such default (if Animas failed to make the
payment required by Section 3.1 of this Agreement) or thirty (30) days in which
to cure such default (if Animas failed to deliver the License Shares required
by Section 3.2 of this Agreement). Debiotech may terminate this Agreement
immediately if such default remains uncured after such cure period.
	 
	 	(b)  	Termination for Other Material Default by Animas. If Animas
materially breaches Section 2.4, 2.6 or 3.5 of this Agreement, Debiotech may
give written notice to Animas specifying the nature of such breach in
reasonable detail and Animas shall have ninety (90) days in case of breach of
Section 2.4 or 2.6, fifteen (15) days in case of breach of Section 3.5 (after
receipt of Debiotech’s written notice) in which to cure such breach. Debiotech
may terminate this Agreement immediately if such material breach remains
uncured after such applicable cure period. The parties agree that, except in
cases in which the breached obligation of Animas would involve a duty to
achieve a specific result, the resumption of reasonable commercial efforts and
not the achievement of any specific result by Animas shall be deemed to be a
cure by Animas. In the event a Sub-licensee materially breaches Section 2.4 of
this Agreement, Debiotech may give written notice to Animas specifying the
nature of such breach in reasonable detail and Animas shall have ninety (90)
days in which to cure such breach or terminate such sublicense agreement.
Debiotech may terminate this Agreement, in addition to other remedies, if such
material breach remains uncured after such ninety (90)

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

days cure period and the sublicense agreement has not been terminated. For the
avoidance of doubt, for purposes of the previous sentence, if the Sub-licensee’s
activities causing the breach effectively cease, such cessation shall be deemed a
cure of the breach. For the avoidance of doubt, Animas shall not be considered
in material breach of Section 2.4 if the actions or activities causing such
breach are beyond the reasonable control of Licensees (which control may require
reasonable additional features and/or labeling to limit use outside the Field,
without the need to obtain additional regulatory approvals).

If there is a dispute as to whether this Agreement has in fact been materially
breached, Animas shall be entitled to require that the matter be determined by
binding baseball arbitration in accordance with Section 16.2 of this Agreement,
in which event the ninety (90)-day period for curing such breach shall not
commence until a final decision has been rendered in such arbitration proceeding.

	 	(c)  	Termination if Change of Control: (i) In the event a Change of
Control occurs prior to Commercial Launch, during the one hundred eighty (180)
day period following such Change of Control, Debiotech may, upon sixty (60)
days prior written notice, notify Animas of its intent to terminate this
Agreement, unless Animas provides adequate assurance to Debiotech (i) that
Animas (or its successor) is interested in developing and attempting to
commercialize the Debiotech Pump in a manner that is economically feasible and
attractive to both parties, and (ii) that Animas will supply adequate resources
for such development. Debiotech may terminate this Agreement immediately if
adequate assurance of appropriate and effective efforts and resources is not
received within such sixty (60) days period.

(ii) Debiotech may, as its sole remedy, terminate this Agreement at any time
after a Change of Control if Animas (or its successor) does not spend at least
****** in developing, marketing and/or selling the Pump Products,
beginning in the first Year following a Change of Control. For the avoidance of
doubt, the ****** minimum spending requirement is not intended to provide any
indication as to the level of reasonable commercial efforts to be used under
Section 2.6 of this Agreement.

	 	(d)  	Termination for Bankruptcy. If Animas is adjudicated bankrupt,
if bankruptcy, insolvency, reorganization, Chapter 11, debt adjustment or
liquidation proceedings, including an involuntary proceeding, are instituted
against Animas and not dismissed within one hundred eighty (180) days after the
institution thereof, if a receiver or trustee is appointed for Animas and its
assets, or if Animas makes a general assignment for the benefit of its
creditors, Debiotech may terminate this Agreement immediately.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

15.3 Consequences of Termination.

Upon termination of this Agreement, under this Section 15,

	 	(a)  	Each party shall pay to the other party any amounts actually
earned, due and owing under this Agreement through and including the
termination date; and, without prejudice to Animas’ right to recover damages,
any amount paid by Animas to Debiotech shall be kept by Debiotech (with no
restitution to be made) except to the extent expressly provided otherwise;
except Animas shall be relieved from any obligation to make any payment
pursuant to Section 3.4 of this Agreement unless the Additional License Fee
fell due prior to the termination notice.
	 
	 	(b)  	In the event of termination pursuant to Section 15.1(c) of this
Agreement, Debiotech shall pay Animas $3.5 million in cash.
	 
	 	(c)  	Debiotech’s audit rights pursuant to Section 4.7 of this
Agreement shall survive for a one-year period following termination. Sections
8.11, 9,10, 11, 12, 14, 15 and 16 of this Agreement shall survive indefinitely
following termination.
	 
	 	(d)  	Except with respect to a breach pursuant to Section 15.1 (b) or
(c), the License and all rights under this Agreement shall become non-exclusive
for a period of one hundred eighty (180) days following termination.
	 	 
	 	(e)  	Following such one hundred eighty (180) day transition period,
or otherwise immediately following termination pursuant to Section 15.1 (b) or
(c),

	 	(i)  	Debiotech’s license rights under any Animas
invention pursuant to Section 13.1 of this Agreement shall survive and
become non-exclusive and extend also in the Field and be non-royalty
bearing;
	 
	 	(ii)  	Rights to any joint invention pursuant to Section
13.1 of this Agreement shall survive and become non-exclusive and
non-royalty bearing for both Animas and Debiotech.
	 
	 	(iii)  	Debiotech’s rights to use any Animas development
pursuant to Section 13.2 of this Agreement shall survive and be
non-royalty bearing. Debiotech’s rights to use any Animas development
pursuant to Section 13.2 of this Agreement shall further extend into the
Field for a limited period of 2 years following termination date royalty
free.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	(iv)  	Debiotech’s perpetual license rights under any
patent assigned to Animas pursuant to Section 13.4 of this Agreement
shall survive and extend also in the Field and be non-royalty bearing.
	 
	 	(v)  	Each party shall return to the other party all
copies of such other party’s confidential information provided in
connection with this Agreement.
	 
	 	(vi)  	Animas shall deliver a letter to Debiotech
confirming expressly that this Agreement has been terminated and that,
except as set forth in Section 13.1, Animas has no further rights to
Debiotech Intellectual Property.
	 
	 	(vii)  	If Animas decides to discontinue selling and/or
distributing the Debiotech Pump in the USA, Animas shall use reasonable
commercial efforts to transfer to Debiotech, to the extent allowed by
law, any FDA Approval obtained for the Debiotech Pump, together with the
FDA Submission and correspondence with the FDA related thereto, promptly
after the six months transition period. For the avoidance of doubt, this
paragraph is not intended to extend to Animas any additional rights not
otherwise set forth in this Agreement.

16. Miscellaneous.

16.1 Mediation and Arbitration. Except as otherwise provided in this Agreement or
the Micro-Needle Agreement, any dispute, controversy or claim arising under, out of or
relating to this Agreement or the Micro-Needle Agreement, and any subsequent amendments
of those Agreements, including, without limitation, their formation, validity, binding
effect, interpretation, performance, breach or termination, as well as non-contractual
claims, between the parties as well as their Affiliates, shall be submitted to
mediation in accordance with the WIPO Mediation Rules. The place of mediation shall be
Philadelphia, Pennsylvania. The language to be used in the mediation shall be English.

If, and to the extent that, any such dispute, controversy or claim has not been
settled pursuant to the mediation within sixty (60) days of the commencement of the
mediation, it shall, upon the filing of a Request for Arbitration by either party,
be referred to and finally determined by arbitration in accordance with the WIPO
Arbitration Rules. Alternatively, if, before the expiration of the said period of
sixty (60) days, either party fails to participate or to continue to participate in
the mediation, the dispute, controversy or claim shall, upon the filing of a Request
for Arbitration by the other party, be referred to and finally determined by
arbitration in accordance with the WIPO Arbitration Rules. The arbitral tribunal
shall consist of three (3) arbitrators, one to be appointed by Animas, one to be
appointed by

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Debiotech and a third to be appointed by the two arbitrators so selected, or, if
they cannot agree on a third arbitrator, by the WIPO Arbitration Center. The place
of arbitration shall be Geneva, Switzerland. The language to be used in the
arbitral proceedings shall be English.

The decision of the arbitrators shall be final and binding upon the parties, and the
expenses of the arbitration (including without limitation any award of arbitration
costs to the prevailing party, provided that, as a guidance, the parties expect the
arbitrators to limit such costs to be paid by the losing party to an amount not
greater than the actual costs incurred by that losing party in presenting its case)
shall be paid as the arbitrators determine. The decision of the arbitrators shall
be executory, and judgment thereon may be entered by any court of competent
jurisdiction. Notwithstanding anything contained in this Section to the contrary,
each party shall have the right to institute judicial proceedings for interim relief
against the other party or anyone acting by, through or under such other party, in
order to enforce the instituting party’s rights hereunder through interim orders for
specific performance, injunction or similar equitable relief in connection with a
breach of Section 2.1 (Exclusive License) or Section 14 (Confidentiality and
Nonsolicitation) hereof.

16.2 Baseball Arbitration. Notwithstanding anything to the contrary contained
herein, any dispute which this Agreement explicitly specifies shall be resolved
pursuant to this Section 16.2 shall be determined in accordance with the procedure
specified in Section 16.1, superseded by the arbitration procedure specified in this
Section 16.2.

There shall be no mediation. The Request for baseball Arbitration may be filed by
either party at any time before, during or after the period of exchange of proposals
described hereunder.

If a party desires to resolve a matter which this Agreement expressly provides shall
be determined under this Section 16.2, such party (the “Initiating Party”) shall
give written notice to the other party (the “Responding Party”) containing a
complete written proposal of the resolution for the matter in dispute. Within ten
(10) business days after receipt of any such notice, the Responding Party shall
submit to the Initiating Party a written counter proposal. The Initiating Party
shall then have two (2) business days after receipt of the counterproposal in which
to decide whether to modify its proposal by giving written notice of its revised
proposal to the Responding Party. The Responding Party shall then have two (2)
business days after receipt of the revised proposal in which to decide whether to
modify its proposal by giving written notice of its revised proposal to the
Initiating Party. This process shall continue with each party sending alternate
proposals to the other party until such time as the earliest of (1) the parties
reach agreement on how to resolve the dispute, (2) one of the parties fails to
respond within two (2) business days after receipt of a proposal from the other
party, or (3) a party determines that it is unwilling to change

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

its proposal further. In the event of clause (2) or (3) of the foregoing sentence,
either party may give written notice (a “Baseball Notice”) to other of its election
to require the submission of their last, best, written proposals (each a “Sealed
Proposal”) within three (3) business days after receipt of the Baseball Notice.
Each party shall submit its Sealed Proposal directly to the WIPO and the WIPO shall
not give any Sealed Proposal to the other party hereto until both such Sealed
Proposals have been received by WIPO. If a party fails timely to submit a Sealed
Proposal, it shall be deemed to have submitted its last written proposal as its
Sealed Proposal.

There shall be no further exchange of written briefs other than the Request for
baseball Arbitration and the Answer to the Request and the Sealed Proposals, except
with special permission of the arbitral tribunal. Within three weeks after the
appointment of the arbitrators, a hearing shall be held. Each party shall be
afforded such amount of time as is reasonable for the presentation of its case at
the hearing, and the hearing shall be sequenced in such a manner, as the arbitrators
shall determine to be commercially reasonable. The arbitrators shall select one of
the party’s Sealed Proposals within five (5) business days after conclusion of the
hearing. The arbitrators shall be limited to awarding only one or the other of the
two Sealed Proposals submitted, without modification. The arbitrator shall be
guided by what is equitable under the circumstances and in accordance with the
principles set forth in the relevant provisions of this Agreement. The selected
Sealed Proposal shall become the arbitrator’s final and binding decision and award,
without any modification. Reasons should not be stated in the award issued within
five (5) business days as provided hereabove, but should be provided subsequently in
a separate document, not to be deemed part of the award.

16.3 Notices. Any notice or election under this Agreement shall be in writing and
shall be given by express commercial delivery service or by fax and by certified mail
to the intended recipient at its address as indicated below or as changed by notice to
the other party given pursuant to this Section 16.1. Notices sent by commercial
delivery service for which delivery is refused shall be deemed received as of the date
delivery is refused. Notices sent by fax and by certified mail shall be deemed
received as of the date of receipt by fax (and if the fax is not received, as of the
date of delivery of the certified mail or the refusal thereof). Notices to Animas shall
be addressed to:

                    Animas Corporation

                    200 Lawrence Drive

                    West Chester, PA 19380

                    Attention: Katherine D. Crothall

                    fax: 484-568-1407

with a copy to:

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

                    Animas Corporation

                    200 Lawrence Drive

                    West Chester, PA 19380

                    Attention: Deborah Lofton

                    Fax: 484-356-1742

Notices to Debiotech shall be addressed to:

                    Debiotech, S.A.

                    28 Avenue de Sevelin

                    CH-1004 Lausanne

                    Switzerland

                    Attention: Dr. Frederic Neftel

                    fax: +41 21 623 6079

with a copy to:

                    Laurent Hirsch

                    8 Rue Eynard

                    CH-1205 Geneva

                    Switzerland

                    fax: +41 22 318 3010

16.4 Governing Law. This Agreement shall be governed first by the Unidroit
Principles, International Commercial Contracts 2004. If these Unidroit Principles of
International Commercial Contracts 2004 do not provide for an applicable provision they
shall be supplemented by the laws of Switzerland.

However, Articles 3.4 and 3.5 of the Unidroit Principles relating to mistake shall
not apply (as it is expressly provided in Article 3.19 not to be mandatory) and no
party may avoid this Agreement for any mistake.

16.5 Severability. If any provision of this Agreement is invalid or unenforceable
in whole or in part in a particular context, the balance of this Agreement shall
nevertheless remain in effect and the invalid or unenforceable provision shall be
enforced to the extent permissible in accordance with the intent of the parties.

16.6 Assignment. This Agreement (including assignment of contractual rights and
transfer of contractual obligations) may not be assigned by Debiotech without Animas’
consent except to Affiliates or to any person who succeeds to all or a substantial
portion of the MEMS Pump Business, as long as Debiotech remains jointly and severally
liable with the assignee until Commercial Launch. For purposes of

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

clarification, the consent requirements contained in this Section 16.6 shall not be
required in the case of any proposed transaction or series of simultaneous
transactions involving the assets and/or liabilities of Debiotech that are executed
in connection with a reorganization of Debiotech, the end result of which (after the
closing of all such transactions) is no change in ultimate ownership or control of
all or substantially all of the assets relating to the MEMS Pump Business conducted
by Debiotech as of the Agreement Date, including all components, contracts, and
other assets and liabilities constituting Debiotech Intellectual Property. In the
event Debiotech transfers or assigns the MEMS Pump Business or transfers or assigns
an Affiliate as described in Section 1.9 of this Agreement, such transfer or
assignment shall not diminish any rights of Licensees to intellectual property
existing prior to such transfer or assignment, or be disruptive to the Development
Program.

This Agreement (including assignment of contractual rights and transfer of
contractual obligations) may not be assigned by Animas except to Affiliates or to
any person who succeeds to all or a substantial portion of Animas business.

Any attempted assignment of this Agreement in violation of this Section 16.6 without
the prior written consent of the other party (not to be unreasonably withheld) shall
be null and void.

In the event of a sale of substantially all the MEMS Pump Business to a third party,
except as provided in the following sentence, Animas shall not be entitled to any
technology and know how owned by Debiotech’s successor other than that associated
with the transferred MEMS Pump Business. Any such intellectual property which
Debiotech has incorporated in the Debiotech Pump shall be subject to the License.

Notwithstanding anything to the contrary contained in this Agreement, Debiotech
shall not be entitled to Section 13.2 Rights on any developments made following a
Change of Control; provided, however, Debiotech shall be entitled to Section 13.2
Rights on developments made after a Change of Control only with respect to
developments made solely by individuals who were employees of Animas prior to a
Change of Control and to the extent that such employee did not use, obtain or have
access to any information from Animas’ successor or any new Affiliate of Animas.

16.7 No Joint Venture. This Agreement is intended to create licenses of certain
patents, trade secrets and copyrights. Nothing herein shall be deemed to constitute a
partnership or joint venture. The Parties are not employees or legal representatives
of the other party for any purpose. Neither Party shall have the authority to enter
into any contracts or agreements in the name of or on behalf of the other party.

16.8 Waiver. No waiver by either party of any violations or nonperformance by the
other party of any of its obligations under this Agreement shall be deemed to be a
waiver of

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

any subsequent violation or nonperformance of the same or any other covenant, nor
shall any forbearance by any party be deemed a waiver by such party of its rights or
remedies with respect to a violation or nonperformance.

16.9 Tax Cooperation. All amounts payable by Animas Group under this Agreement
shall be reduced for any taxes that are required to be withheld from the payment, and
Animas Group will pay such amounts promptly to the relevant governmental agency and
provide Debiotech reasonable proof of the payment of such taxes. Each party will
reasonably cooperate with the other to provide such forms or other documentation that
would preclude the withholding of tax from such payments, and will reasonably cooperate
to recover such withheld taxes as appropriate. If any payments to be made hereunder
are subject to the payment of value added tax ( or similar tax) by Animas Group, such
value added tax shall be paid by Animas in addition to the amounts as stated in this
Agreement and each party shall cooperate as reasonably requested by the other to
recuperate any value added or other tax which are normally recoupable in the
international context.

16.10 Interest. The interest rate applicable to overdue payments shall be 2 points
over the LIBOR (London Interbank Offered Rate for US dollars) at one month for the
first month of delay, 4 points over the LIBOR (London Interbank Offered Rate for US
dollars) at three months for the next three months of delay, and 6 points over the
LIBOR (London Interbank Offered Rate for US dollars) at six months for any period
thereafter; provided that, the interest rate applicable to payments that are subject to
a reasonably arguable dispute shall be 2 points over the LIBOR (London Interbank
Offered Rate for US dollars) at six months for the entire period the payments are
withheld in good faith. Interest shall be due for the whole period from the date
initially due until the date payment is received by the other party, compounded on a
six months basis. However, no interest shall be due to the extent payment is made
within a grace period of fifteen (15) days after special notice specifying the amount
due and requesting payment within the fifteen (15) day period. Interest at such rate
shall not be deemed to constitute damages for the purposes of the limitation set forth
in Section 9.2 of this Agreement.

16.11 Set-Off. If at any time Animas asserts any claim or cause of action under
Section 16.1 or Section 16.2 of this Agreement, then at Animas’ election, Animas may
set-off any portion or all of the amounts contained in such claim or cause of action
against amounts payable by Animas to Debiotech hereunder, subject to the limitation
below. Upon resolution of such claim or cause of action, if it is determined that
Animas had set-off a greater amount than the actual damages awarded with respect to
such claim or cause of action, Animas shall return such excess amounts, together with
interest calculated as hereabove. Any amounts by which such actual damages awarded
exceed such amounts previously set-off may continue to be set-off in the sole
discretion of Animas. Notwithstanding the foregoing, Animas’ right to set-off any
claim against

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

royalties due to Debiotech under Section 4.1 of this Agreement shall only apply to
royalties in excess of ******.

16.12 Hardship. In the event the conditions upon which the parties rely at the time
of entering into this Agreement are drastically modified, so that any party would
suffer severe consequences from maintaining the terms of this Agreement, which could
not have been reasonably foreseen at the time of entering into this Agreement, the
parties agree to discuss in good faith appropriate modifications to the terms of this
Agreement in view of the new circumstances and to the extent equitable to both parties
(Article 6.2.2 of the Unidroit Principles shall not apply).

16.13 Entire Agreement. This Agreement, including its exhibits, constitutes the
entire agreement between the parties pertaining to the subject matter hereof and
supersedes all prior and contemporaneous agreements and understanding of the parties,
whether written or oral. No amendment or modification of this Agreement shall be valid
or binding unless in writing and executed by the party to be bound.

16.14 Headings. The headings for each article and section in this Agreement have
been inserted for convenience or reference only and are not intended to limit or expand
on the meaning of the language contained in the particular article or section.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

IN WITNESS WHEREOF, each of the parties has caused this Agreement to be executed on its behalf by
its duly authorized representatives.

	 	 	 	 	 	 	 
	 	 	Debiotech S.A.	 	 
	 
	 	 	 	 	 	 
	

	 	By:
	 	/s/ Frédéric Neftel
	 	date: 10/29/04
	 	 	 	 	 	 	 
	

	 	 	 	Frédéric Neftel , its CEO	 	 
	 
	 	 	 	 	 	 
	 	 	Animas Corporation	 	 
	 
	 	 	 	 	 	 
	

	 	By:
	 	/s/ Katherine D. Crothall
	 	date: 10/29/04
	 	 	 	 	 	 	 
	

	 	 	 	Katherine D. Crothall, its CEO	 	 

	 	 	 
	Exhibit A:

	 	Description of Existing Debiotech Intellectual Property
	Exhibit B:

	 	Development Plan and Specifications for the Debiotech Pump
	Exhibit C:

	 	Debiotech Research & Engineering Costs
	Exhibit D:

	 	List of Privileged Shareholders
	Exhibit E:

	 	Subscription Agreement
	Exhibit F:

	 	intentionally left blank
	Exhibit G:

	 	intentionally left blank
	Exhibit H:

	 	Royalty Rate Schedule
	Exhibit I

	 	deliverables to be provided by Debiotech as part of 510k filing

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Exhibit A

Description of Existing Debiotech Intellectual Property

******

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Exhibit B

Development Plan and Specifications for the Debiotech Pump

******

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Exhibit C

Debiotech Research & Engineering Costs

******

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Exhibit D

List of Privileged Shareholders

Katherine D. Crothall

Graeme Crothall

William A. Graham, IV

 

 

Exhibit E

Subscription Agreement

	 	1.  	Subscription. The undersigned (the “Subscriber”) hereby subscribes for Four
Hundred Thousand (400,000) shares of Common Stock, $0.01 par value (the “Shares”) of Animas
Corporation (the “Company”), in partial consideration for the Subscriber granting licenses
dated as of the date hereof to the Company of certain technology. The parties acknowledge
and agree that the consideration from Subscriber for the Shares shall be the product of
400,000 multiplied by the last reported sale price of one share of the Company’s Common
Stock as reported on the Nasdaq National Market on the last trading day immediately
preceding the date of this Agreement.
	 
	 	2.  	Representations, Warranties and Covenants of the Subscriber. By executing this
Subscription Agreement (the “Agreement”), the Subscriber makes the following
representations, declarations, warranties and covenants to the Company, with the intent and
understanding that the Company will rely thereon:

	 	a.  	The Shares have not been registered under the Securities Act of 1933,
as amended (the “Securities Act”) or any state securities laws. Subscriber
understands that the offering and sale of the Shares are intended to be exempt from
registration under the Securities Act, by virtue of Section 4(2) thereof and the
provisions of Regulation D promulgated thereunder, based, in part, upon the
representations, warranties and agreements of Subscriber contained in this
Agreement. Subscriber is aware that the Shares are “restricted securities” and
that it must bear the substantial economic risks of the investment in the Shares
indefinitely because the Shares may not be sold, hypothecated or otherwise disposed
of unless subsequently registered under the Securities Act and applicable state
securities laws or an exemption from such registration is available. Subscriber is
familiar with Rule 144 promulgated under the Securities Act and understands the
resale limitations imposed thereby and by the Securities Act and the rules
thereunder generally. Subscriber understands that legends shall be placed on any
Share certificates to the effect that they have not been registered under the
Securities Act or applicable state securities laws and appropriate notations
thereof will be made in the Company’s stock books.
	 
	 	b.  	Subscriber has adequate means of providing for its current financial
needs and foreseeable contingencies and has no need for liquidity of the investment
in the Shares for an indefinite period of time. Subscriber has significant prior
investment experience, including investment in non-listed and nonregistered
securities. Subscriber is knowledgeable about investment considerations and risk
factors in similar companies. Subscriber’s overall commitment to investments which
are not readily marketable is not excessive in view of its net worth and financial
circumstances and the purchase of the Shares will not cause such commitment to
become excessive. The investment is a suitable one for Subscriber. Subscriber
meets the requirements of at least one of the definitions of an “accredited
investor” as defined in Rule 501(a) of Regulation D under the Securities Act.
	 
	 	c.  	Subscriber has full power and authority to accept the Shares and to
execute and deliver this Agreement and all other related agreements or certificates
and to carry out the provisions hereof and thereof, and make an investment in the
Company, and this Agreement constitutes a legal, valid and binding obligation of
Subscriber enforceable in accordance with its terms. The execution of this
Agreement will not violate or be in

 

 

	 	   	conflict with any order, judgment,
injunction, agreement or controlling document to which Subscriber is a party or by
which it is bound.
	 
	 	d.  	Neither the Securities and Exchange Commission nor any state securities
commission has approved the Shares.
	 
	 	e.  	Subscriber and the Subscriber’s accountants, lawyers and financial
advisors, if any (the “Advisors”), had the opportunity to obtain any information,
to the extent the Company had such information in Company’s possession or could
acquire it without unreasonable effort or expense, to verify the accuracy of the
information and all documents received or reviewed in connection with the
acquisition of the Shares and have had the opportunity to ask representatives of
the Company questions and receive answers concerning the terms and conditions of
this particular investment.
	 
	 	f.  	Subscriber is unaware of, is in no way relying on, and did not become
aware of the offering of the Shares through or as a result of, any form of general
solicitation or general advertising including, without limitation, any article,
notice, advertisement or other communication published in any newspaper, magazine
or similar media or broadcast over television or radio, in connection with the
offering and sale of the Shares and did not become aware of the offering of the
Shares and is not purchasing the Shares through or as a result of any seminar or
meeting to which Subscriber was invited by, or any solicitation of a subscription
by, a person not previously known to it in connection with investments in
securities generally.
	 
	 	g.  	Subscriber has taken no action which would give rise to any claim by
any person for brokerage commissions, finders’ fees or the like relating to the
Shares or the transactions contemplated hereby and thereby.
	 
	 	h.  	Subscriber or its representative, as the case may be, together with the
Advisors, have such knowledge and experience in financial, tax, and business
matters, and, in particular, investments in the Shares, so as to enable them to
utilize the information made available to them in connection with the offering of
the Shares to evaluate the merits and risks of an investment in the Shares and to
make an informed investment decision with respect thereto.
	 
	 	i.  	Subscriber is not relying on the Company or any of its employees or
agents with respect to the legal, tax, economic and related considerations of an
investment in the Shares, and Subscriber has relied on the advice of, or has
consulted with, only its own Advisors.
	 
	 	j.  	Subscriber is acquiring the Shares solely for its own account for
investment and not with a view to resale or distribution thereof, in whole or in
part. Subscriber has no contract, undertaking, agreement or arrangement, formal or
informal, oral or written, with any person to sell or transfer all or any part of
the Shares, and Subscriber has no plans to enter into any such contract,
undertaking, agreement or arrangement.
	 
	 	k.  	Subscriber represents to the Company that the representations and
warranties and any information which Subscriber has heretofore furnished or
furnishes with this Agreement to the Company are true, complete and accurate and
may be relied upon by the Company in

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	determining the availability of an exemption
from registration under Federal and state securities laws in connection with the
offering of the Shares. Subscriber further represents and warrants that Subscriber
will notify and supply corrective information to the Company immediately upon the
occurrence of any change therein occurring prior to the Company’s issuance of the
Shares.
	 
	 	l.  	Within five days after receipt of a request from the Company,
Subscriber will provide such information and deliver such documents as may
reasonably be necessary to comply with any and all laws and ordinances to which the
Company is subject.
	 
	 	m.  	Any certificate(s) evidencing the Shares will bear a legend
substantially similar to the following:

     THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE. THE SHARES MAY NOT BE
TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SUCH ACT AND SUCH
LAWS.

	 	3.  	Registration Rights.

	 	a.  	Definitions.

	 	1.  	“Business Day” means any day other than a
Saturday, Sunday or a day on which banks are authorized to close in
the Commonwealth of Pennsylvania.
	 
	 	2.  	“Registrable Securities” means the Shares
until the earlier of the date on which (i) a registration statement
covering such Securities has been declared effective by the
Commission and such Securities have been disposed of pursuant to
such effective registration statement, (ii) such Securities are sold
under circumstances in which all the applicable conditions of Rule
144 (or any similar provisions then in force) under the Securities
Act are met, or such Securities may be sold in a single transaction
under Rule 144(k) (or any similar provision then in force) under the
Securities Act, (iii) the Company has delivered a new certificate or
other evidence of ownership for such Securities not bearing a legend
restricting further transfer and such Securities may be resold
without registration under the Securities Act, or (iv) such
Securities shall cease to be held by Subscriber.
	 
	 	3.  	“Registration Statement” means the
registration statements of Company relating to the registration for
sale of Securities (as defined below), including the prospectus
included therein, all amendments and supplements thereto (including
post-effective amendments) and all exhibits and material
incorporated by reference therein.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	4.  	“Securities” means shares of Common
Stock, $0.01 par value of the Company.

	 	b.  	Piggyback Registration Rights.

	 	1.  	Whenever Company proposes to register any
Securities for the account of any of its stockholders under the
Securities Act, which Securities include shares of the Company’s
Common Stock held by stockholders not having any contractual
registration rights, and not including any registration relating to
employee benefit plans, Company shall give Subscriber written notice
of Company’s intent to do so no later than two (2) Business Days

after the filing date of the Registration Statement effecting such
registration. Within two (2) Business Days after the receipt of such
notice, Subscriber shall give Company written notice stating the
number of shares of Registrable Securities it wishes to be
registered. Company will use commercially reasonable efforts to
cause to be included in such registration all of the Registrable
Securities that Subscriber requests to be registered subject to any
limitations pursuant to Section 3(b)(2) below; all to the extent
requisite to permit the sale by the Subscriber of such Registrable
Securities in accordance with the method of sale applicable to the
other Securities included in such Registration Statement on behalf of
the other selling stockholders; provided, however,
that if, at any time after giving written notice of its intention to
register any Securities and prior to the effective date of a
Registration Statement filed in connection with such registration,
the Company shall determine for any reason not to register or to
delay registration of such securities, the Company may, at its
election, give written notice of such determination to Subscriber
and, thereupon: (a) in the case of a determination not to register,
shall be relieved of its obligation to register any Registrable
Securities in connection with such registration, and (b) in the case
of a delay in registering, shall be permitted to delay registering
any Registrable Securities for the same period as the delay in
registering such other securities.
	 
	 	2.  	The Company shall not be obligated to
include any Registrable Securities in a registration statement filed
on Form S-4, Form S-8 or such other similar successor forms then in

effect under the Securities Act. If a Registration Statement
involves an underwritten offering and the managing underwriter
advises the Company in writing that, in its opinion, the number of
securities requested to be included in such Registration Statement
exceeds the number which can be sold in such offering without
adversely affecting the offering, the Company will include in such
Registration Statement only the number of such securities, if any,
which the Company is so advised can be sold in such offering without
adversely affecting the offering, determined as follows. The
Subscriber acknowledges and agrees that its shares will only be
included after all Securities desired to be included by the Company
or by any party with contractual registration rights are included.
Thereafter, the Subscriber’s

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	shares will only be included to the
extent determined by multiplying (a) the remaining Securities able
to be registered as determined by the managing underwriter, by (b)
the fraction of (i) the number of Registrable Securities that the
Subscriber proposes to include in such registration divided by (ii)
the total number of Securities proposed to be sold in such offering
by all remaining holders without contractual registration rights.

	 	c.  	Holdback Agreement. If Company at any time shall register
shares of Securities under the Securities Act (including any registration pursuant
to Section 3) for sale to the public, upon request and if required by the managing
underwriter, then Subscriber shall not (provided Subscriber is participating in
such registration) sell publicly, make any short sale of, grant an option for the
purchase of, or otherwise dispose publicly of, any shares of Registrable Securities
(other than those Securities included in such registration pursuant to Section 3)
without the prior written consent of Company or the managing underwriter of the
offering
for a period designated by Company in writing, which period shall not begin more
than ten (10) days prior to the effectiveness of the registration statement pursuant
to which such public offer will be made and shall not last more than one hundred
eighty (180) days after the effective date of such registration statement; provided
that Subscriber shall not be obligated to refrain from any of the foregoing for a
period that is greater than the minimum period required of any executive officer or
director of Company.
	 
	 	d.  	Underwriting Arrangement. If the offering is an underwritten
one, then such right of Subscriber to registration pursuant to Section 3(b) shall
be conditioned upon Subscriber’s participation in such underwriting and the
inclusion of Subscriber’s Registrable Securities in the underwriting to the extent
provided herein. Subscriber shall enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for such underwriting.
If Subscriber disapproves of the terms of any such underwriting, Subscriber may
elect to withdraw therefrom by written notice to the Company and the underwriter no
later than ten (10) Business Days prior to the effectiveness of such Registration
Statement. Any Registrable Securities excluded or withdrawn from such underwriting
shall be withdrawn from such registration.
	 
	 	e.  	Subscriber’s Cooperation

	 	1.  	If Subscriber desires to sell in any
Registration Statement, Subscriber will furnish to the Company such
information as the Company may reasonably require in connection with
the Registration Statement (and the prospectus included therein).
Subscriber may not participate in any offering unless Subscriber (i)
agrees to sell its Registrable Securities to be sold on the basis
provided in any agreement governing the offering and (ii) completes
and executes all customary questionnaires, indemnities, and other
documents reasonably required in connection with the offering.
Subscriber may not include any of its Registrable Securities in any
Registration Statement pursuant to this Agreement unless and until
Subscriber furnishes to the Company in writing, within two (2)
Business Days after receipt of a written request therefor, such
information specified in Item 507 of Regulation S-K under the
Securities Act or such other information as the Company may
reasonably request for use in connection

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	with such Registration
Statement or Prospectus or preliminary Prospectus included therein
and in any application to the NASD. Subscriber agrees to furnish
promptly to the Company all information required to be disclosed in
order to make all information previously furnished to the Company by
Subscriber not materially misleading.
	 
	 	2.  	Subscriber will not effect sales of
Registrable Securities pursuant to a registration statement (or
deliver a prospectus to any purchaser) after receipt of notice from
the Company to suspend sales to permit the Company to correct or
update a registration statement or prospectus until the Company
advises Subscriber that the registration statement has been amended
or that conditions no longer exist which would require such
suspension.
	 
	 	3.  	In connection with any offering,
Subscriber will not use any offering document, offering circular or
other offering materials with respect to the
offer or sale of Registrable Securities, other than the prospectuses
provided by the Company and any documents incorporated by reference
therein.

	 	f.  	Indemnification and Contribution.

	 	1.  	In the event of a registration of any
Registrable Securities under the Securities Act pursuant to Section
3 by Subscriber, Company will indemnify and hold harmless
Subscriber, and each other person, if any, who controls Subscriber
within the meaning of the Securities Act, and each employee, officer
and trustee of Subscriber against any losses, claims, damages or
liabilities, joint or several, to which Subscriber, or each such
controlling person, employee, officer or trustee may become subject
under the Securities Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise
out of or are based upon any untrue statement or alleged untrue
statement of any material fact contained in any registration
statement under which such Registrable Securities was registered
under the Securities Act pursuant to Section 3, any preliminary
prospectus or final prospectus contained therein, or any amendment
or supplement thereof, or arise out of or are based upon the
omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements
therein not misleading, and will reimburse Subscriber, and each such
controlling person, employee, officer or trustee for any legal or
other expenses reasonably incurred by them in connection with
investigating or defending any such loss, claim, damage, liability
or action; provided that Company will not be liable in any such case
if and to the extent that any such loss, claim, damage or liability
(x) arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission so made in
conformity with information furnished by Subscriber or any such
controlling person, employee, officer or trustee in writing
specifically for use in such registration statement or prospectus;
(y) with

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	respect to the preliminary prospectus, results from the
fact that Subscriber sold Securities to a person to whom there was
not sent or given, at or prior to the written confirmation of such
sale, a copy of the prospectus, as amended or supplemented, if the
Company shall have previously furnished copies thereof to Subscriber
in accordance with this Agreement and said prospectus, as amended or
supplemented, would have corrected such untrue statement or
omission; or (z) as a result of the use by an indemnified person of
any prospectus upon receipt of a notice from the Company of the
existence of any fact or the happening of any event that makes any
statement of a material fact made in any such Registration
Statement, the related prospectus, any amendment or supplement
thereto, or any document incorporated by reference therein untrue,
or that requires the making of any additions to or changes in any
such Registration Statement or the related prospectus in order to
make the statements therein not misleading.
	 
	 	2.  	In the event of a registration of any
Registrable Securities under the Securities Act pursuant to Section
3 by Subscriber, Subscriber will indemnify and hold harmless
Company, each person, if any, who controls Company within the
meaning of the Securities Act, officer of Company who signs the
registration statement, director of Company, underwriter and
person who controls any underwriter within the meaning of the
Securities Act, against all losses, claims, damages or liabilities,
joint or several, to which Company or such officer, director,
underwriter or controlling person may become subject under the
Securities Act or otherwise, insofar as such losses, claims, damages
or liabilities (or actions in respect thereof) arise out of or are
based upon any untrue statement or alleged untrue statement of any
material fact contained in the registration statement under which
such Registrable Securities were registered under the Securities Act
pursuant to Section 3, any preliminary prospectus or final prospectus
contained therein, or any amendment or supplement thereof, or arise
out of or are based upon the omission or alleged omission to state
therein a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances in which
they were made, not misleading, and will reimburse Company and each
such officer, director, underwriter and controlling person for any
legal or other expenses reasonably incurred by them in connection
with investigating or defending any such loss, claim, damage,
liability or action; provided that Subscriber will be liable
hereunder in any such case if and only to the extent that any such
loss, claim, damage or liability arises out of or is based upon an
untrue statement or alleged untrue statement or omission or alleged
omission made in reliance upon and in conformity with information
pertaining to Subscriber, as such, furnished in writing to Company by
Subscriber specifically for use in such registration statement or
prospectus. Further notwithstanding anything to the contrary
contained in this paragraph, Subscriber will not be liable for
indemnification pursuant to a registration statement, preliminary
prospectus, final prospectus, or any amendment or supplement thereof,
in an amount in

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	excess of the public offering price of all
Registrable Securities offered by Subscriber therein.
	 
	 	3.  	Promptly after receipt by an indemnified
party hereunder of notice of the commencement of any action, such
indemnified party shall, if a claim in respect thereof is to be made
against the indemnifying party hereunder, notify the indemnifying
party in writing thereof, but the omission so to notify the
indemnifying party shall not relieve the indemnifying party from any
liability which the indemnifying party may have to such indemnified
party other than under this Section and shall only relieve the
indemnifying party from any liability which the indemnifying party
may have to such indemnified party under this Section if and to the
extent the indemnifying party is prejudiced by such omission. In
case any such action shall be brought against any indemnified party
and the indemnified party shall notify the indemnifying party of the
commencement thereof, the indemnifying party shall be entitled to
participate in and, to the extent the indemnifying party shall wish,
to assume and undertake the defense thereof with counsel
satisfactory to such indemnified party, and, after notice from the
indemnifying party to such indemnified party of the indemnifying
party’s election so to assume and undertake the defense thereof, the
indemnifying party shall not be liable to such indemnified party
under this Section for any legal expenses subsequently incurred by
such indemnified party in connection with the defense thereof other
than reasonable costs of investigation and of liaison with counsel
so selected; provided that, if the
defendants in any such action include both the indemnified party and
the indemnifying party and the indemnified party shall have
reasonably concluded that there may be reasonable defenses available
to the indemnified party which are materially different from or
additional to those available to the indemnifying party or if the
interests of the indemnified party reasonably may be deemed to
conflict with the interests of the indemnifying party, then the
indemnified party shall have the right to select a separate counsel
and to assume such legal defenses and otherwise to participate in the
defense of such action, with the expenses and fees of such separate
counsel and other expenses related to such participation to be
reimbursed by the indemnifying party as incurred, it being
understood, however, that the Company shall not, in connection with
such action or similar or related actions or proceedings arising out
of the same general allegations or circumstances, be liable for the
reasonable fees and expenses of more than one separate firm of
attorneys (in addition to any local counsel) at any time for all the
indemnified persons, which firm shall be (x) designated by such
indemnified persons and (y) reasonably satisfactory to the Company.
	 
	 	4.  	In order to provide for just and
equitable contribution to joint liability under the Securities Act
in any case in which either: (i) Subscriber exercises rights under
this Agreement and makes a claim for indemnification pursuant to
this Section but it is judicially determined (by the entry of a
final judgment or decree by a court of competent

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	jurisdiction and
the expiration of time to appeal or the denial of the last right of
appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Section provides for
indemnification in such case, or (ii) contribution under the
Securities Act may be required on the part of any such selling
holder or any such controlling person in circumstances for which
indemnification is provided under this Section; then, and in each
such case, Company and Subscriber will contribute to the aggregate
losses, claims, damages or liabilities to which they may be subject
(after contribution from others) as is appropriate to reflect the
relative fault of Company and Subscriber in connection with the
statements or omissions which resulted in such losses, claims,
damages or liabilities, as well as the relative benefit received by
Company and Subscriber as a result of the offering in question, it
being understood that the parties acknowledge that the overriding
equitable consideration to be given effect in connection with this
provision is the ability of one party or the other to correct the
statement or omission which resulted in such losses, claims, damages
or liabilities, and that it would not be just and equitable if
contribution pursuant hereto were to be determined by pro rata
allocation or by any other method of allocation that does not take
into consideration the foregoing equitable considerations; provided
that, in any such case: (A) Subscriber will not be required to
contribute any amount in excess of the public offering price of all
such Registrable Securities offered by Subscriber pursuant to such
registration statement; and (B) no person or entity guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) will be entitled to contribution from any person
or entity who was not guilty of such fraudulent misrepresentation.
	 
	 	5.  	Notwithstanding anything to the contrary
contained herein, the Company shall not be liable for any settlement
of any such action or proceeding effected without the Company’s
prior written consent, which consent shall not be withheld
unreasonably, and the Company shall not, without the prior written
consent of each indemnified person, which shall not be unreasonably
withheld, settle or compromise or consent to the entry of judgment
on or otherwise seek to terminate any pending or threatened action,
claim, litigation or proceeding in respect of which indemnification
or contribution is required hereunder (whether or not any
indemnified person is a party thereto), unless such settlement,
compromise, consent or termination includes an unconditional release
of each indemnified person from all liability arising out of such
action, claim litigation or proceeding.

	 	g.  	Changes in Securities. If, and as often as, there is any
change in the Securities by way of a stock split, stock dividend, combination or
reclassification, or through a merger, consolidation, reorganization or
recapitalization, or by any other means, then appropriate adjustment shall be made
in the provisions hereof so that the rights and privileges granted by this Section
3 shall continue with respect to the Securities constituting the Shares as so
changed.

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	h.  	Grant and Transfer of Registration Rights. The Company may
grant any registration rights to any other person or entity without the prior
consent of Subscriber. The registration rights granted in this Section 3 may not
be assigned or otherwise transferred.

	 	4.  	Miscellaneous.

	 	a.  	Notices. Notices and other communications between the parties
shall be in the English language. All notices or other communications which are
required or permitted hereunder shall be in writing and may be delivered
personally, sent by prepaid overnight delivery service, sent by prepaid regular
mail or sent by facsimile transmission, addressed as shown on the signature page
hereto or to such other addresses as the parties may provide in writing from time
to time. Any notice or communication shall be deemed to have been given: when
delivered, if personally delivered; on the first Business Day after dispatch, if
sent by reputable overnight delivery service using its next day delivery service;
on the sixth (6th) business day following the date of mailing (as evidenced by the
postmark), if sent by prepaid regular mail; or, on the first Business Day after
facsimile transmission (such date of transmission as provided on a machine
generated confirmation receipt), if sent by facsimile transmission.
	 
	 	b.  	Indemnity. The representations, warranties and agreements made
by the Subscriber herein shall survive consummation of this offering as anticipated
hereby. The Subscriber hereby agrees to indemnify and hold harmless the Company
from and against any and all loss, liability, claim, damage and expense (including,
without limitation, attorneys’ fees and disbursements) suffered or incurred as a
result of a misrepresentation or breach of any warranty or agreement made by the
Subscriber in this Agreement.
	 
	 	c.  	Governing Law, Etc. This Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the Commonwealth of
Pennsylvania. Each of Subscriber and the Company (i) agree that all actions and
proceedings relating to this Subscription Agreement shall be litigated exclusively
in state or federal courts located in Philadelphia, Pennsylvania; (ii) consent to
the jurisdiction and venue of any such court and consents to
service of process in any such action or proceeding by personal delivery or any
other method permitted by law; and (iii) waive any and all rights either of them may
have to object to the jurisdiction of any such court, or to transfer or change the
venue of any such action or proceeding. Notwithstanding the foregoing, each of the
Subscriber and Company agree that no claims relating to the License Agreements shall
be brought in state or federal courts located in Philadelphia, Pennsylvania under
this provision. In the event a claim brought under this Agreement is the same as a
claim which could be brought under either of the License Agreements, provided no
different remedy would be sought under this Agreement, such claim will be brought in
arbitration under the procedures outlined the License Agreements (excluding any
baseball arbitration procedures). All captions of sections are for convenience
only. All pronouns and any variations thereof shall be deemed to refer to the
masculine, feminine, neuter, singular or plural, as the identity of the person or
persons or entity or entities may require. All references to “$” or dollars herein
shall be construed to refer to United States dollars. This Agreement is not
transferable or assignable (including by operation of law) by the Subscriber. The
representations, warranties and agreements contained herein shall be deemed to be
made by and be binding upon the Subscriber and such Subscriber’s heirs, executors,
administrators and successors

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

	 	   	and shall inure to the benefit of the Company and its
successors and assigns. None of the provisions of this Agreement may be waived,
changed or terminated, orally or otherwise, except by a writing signed by the
Company and the Subscriber.
	 
	 	d.  	Counterparts. This Agreement may be executed (including
execution by facsimile) in any number of counterparts and by any combination of the
parties hereto in separate counterparts, each of which counterparts shall be an
original and all of which taken together shall constitute one and the same
agreement.
	 
	 	e.  	Benefits of this Agreement. Nothing in this Agreement shall be
construed to give to any person or corporation other than the Company and
Subscriber any legal or equitable right, remedy or claim under this Agreement; and
this Agreement shall be for the sole and exclusive benefit of the Company and
Subscriber.
	 
	 	f.  	Integration. This Agreement and the license agreements between
Company and Subscriber of even date herewith (including all amendments and
exhibits), contain the entire agreement between the parties with respect to the
subject matter hereof and supersede all other oral or written representations,
statements, or agreements with respect to such subject matter.
	 
	 	   	[Remainder of page is intentionally blank. Signature pages follow.]

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

IN WITNESS WHEREOF, THE PARTIES HAVE EXECUTED THIS SUBSCRIPTION AGREEMENT AS OF THIS ____ DAY OF ____________, 2004.

	 	 	 	 	 	 	 
	DEBIOTECH S.A.	 	ANIMAS CORPORATION
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:
	 	 
	Name:

	Frédéric Neftel
	 	 	Name:
	Katherine D. Crothall	 
	Title:

	CEO
	 	 	Title:
	President and Chief Executive Officer	 

	 	 	 	 	 	 	 
	Address:

	Debiotech, S.A.
	 	 	Address:
	Animas Corporation	 
	

	28 Avenue de Sevelin
	 	 	 	Animas Corporation	 
	

	CH-1004 Lausanne
	 	 	 	200 Lawrence Drive	 
	

	Switzerland
	 	 	 	West Chester, PA 19380	 
	

	Attention: Dr. Frederic Neftel
	 	 	 	Attention: Katherine D. Crothall	 
	

	fax: +41 21 623 6079
 	 	 	 	fax: 484-568-1407	 
	 
	 	 	 	 	 	 
	Copy to:

	Laurent Hirsch
	 	 	Copy to:
	Pepper Hamilton LLP	 
	

	8 Rue Eynard
	 	 	 	3000 Two Logan Square	 
	

	CH-1205 Geneva
	 	 	 	18th and Arch Streets	 
	

	Switzerland
	 	 	 	Philadelphia, PA 19103	 
	

	fax: +41 21 623 6079
 	 	 	 	Attn: Barry M. Abelson, Esq.	 
	

	 	 	 	 	fax: 215-981-4750	 

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Exhibit F

intentionally left blank

 

 

Exhibit G

intentionally left blank

 

 

Exhibit H

Royalty Rate Schedule

******

	******	 	- Material has been omitted and filed separately with the Commission.

 

 

Exhibit I

deliverables to be provided by Debiotech as part of 510k filing

******

	******	 	- Material has been omitted and filed separately with the Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00081-of-00352.parquet"}]]